"medicine_name","eml_section","formulations","indication","combined_with","status","atc_classification","source"
"bcg vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against tuberculosis","","Added","L03AX03","who.int"
"japanese encephalitis vaccine","Recommendations for certain regions","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BA02","who.int"
"japanese encephalitis vaccine","Recommendations for certain regions","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BA03","who.int"
"medicines for covid-19","Medicines for COVID-19","Refer to WHO living guidelines","COVID-19","","Added","nan","who.int"
"abacavir","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Solid: 300 mg tablet (as sulfate)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AF06","who.int"
"abacavir + lamivudine","Fixed-dose combinations of antiretrovirals","Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR02","who.int"
"abacavir + lamivudine + lopinavir + ritonavir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","nan","who.int"
"abiraterone","Hormones and antihormones","Oral > Solid: 250 mg; 500 mg","Malignant neoplasms of prostate","","Added","L02BX03","who.int"
"acetazolamide","Ophthalmological preparations > Miotics and antiglaucoma medicines","Oral > Solid: 250 mg","Primary open-angle glaucoma","","Added","S01EC01","who.int"
"acetic acid","Ear, nose and throat medicines [c]","Local > Otological > drops: 2% in alcohol","Infectious diseases of external ear","","Added","S02AA10","who.int"
"acetylcysteine","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 200 mg per  mL in 10 mL ampoule
Oral > Liquid: 10%; 20%","Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs","","Added","V03AB23","who.int"
"acetylcysteine","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 200 mg per  mL in 10 mL ampoule
Oral > Liquid: 10%; 20%","Acute or subacute hepatic failure","","Removed","V03AB23","who.int"
"acetylsalicylic acid","Antimigraine medicines > For treatment of acute attack","Oral > Solid: 300 to 500 mg","Migraine","","Added","N02BA01","who.int"
"acetylsalicylic acid","Anti-platelet medicines","Oral > Solid: 100 mg","Acute myocardial infarction","","Added","B01AC06","who.int"
"acetylsalicylic acid","Anti-platelet medicines","Oral > Solid: 100 mg","Cerebral ischaemic stroke","","Added","B01AC06","who.int"
"acetylsalicylic acid","Medicines for juvenile joint diseases","Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg","Acute rheumatic fever without mention of heart involvement","","Added","N02BA01","who.int"
"acetylsalicylic acid","Medicines for juvenile joint diseases","Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg","Mucocutaneous lymph node syndrome","","Added","N02BA01","who.int"
"acetylsalicylic acid","Medicines for juvenile joint diseases","Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg","Juvenile idiopathic arthritis","","Added","N02BA01","who.int"
"acetylsalicylic acid","Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg","Pain","","Added","N02BA01","who.int"
"aciclovir","Antiherpes medicines","Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet","Zoster","","Added","J05AB01","who.int"
"aciclovir","Antiherpes medicines","Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet","Varicella","","Added","J05AB01","who.int"
"aciclovir","Antiherpes medicines","Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet","Herpes simplex infections","","Added","J05AB01","who.int"
"aciclovir","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 3% w/w","Herpes simplex keratitis","","Added","S01AD03","who.int"
"aclidinium","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Chronic obstructive pulmonary disease","","Added","nan","who.int"
"activated charcoal","Antidotes and other substances used in poisonings > Non-specific","Oral > Other: powder","Unspecified injury, poisoning or certain other consequences of external causes","","Added","A07BA01","who.int"
"adalimumab","Immunomodulators for non-malignant disease","Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","Axial spondyloarthritis","","Added","L04AB04","who.int"
"adalimumab","Immunomodulators for non-malignant disease","Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","Crohn disease site","","Added","L04AB04","who.int"
"adalimumab","Immunomodulators for non-malignant disease","Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","Rheumatoid arthritis","","Added","L04AB04","who.int"
"adalimumab","Medicines for juvenile joint diseases","Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL","Juvenile idiopathic arthritis","","Added","L04AB04","who.int"
"afatinib","Targeted therapies","","Other specified malignant neoplasms of bronchus or lung","","Added","nan","who.int"
"albendazole","Intestinal anthelminthics","Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))","Echinococcosis","","Added","P02CA03","who.int"
"albendazole","Intestinal anthelminthics","Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))","Ascariasis","","Added","P02CA03","who.int"
"albendazole","Intestinal anthelminthics","Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))","Enterobiasis","","Added","P02CA03","who.int"
"albendazole","Intestinal anthelminthics","Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))","Trichuriasis","","Added","P02CA03","who.int"
"albendazole","Intestinal anthelminthics","Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))","Hookworm diseases","","Added","P02CA03","who.int"
"albendazole","Intestinal anthelminthics","Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))","Cysticercosis","","Added","P02CA03","who.int"
"albendazole","Cysticidal medicines","Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)","Other specified echinococcosis","","Added","P02CA03","who.int"
"albendazole","Cysticidal medicines","Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)","Cysticercosis of central nervous system","","Added","P02CA03","who.int"
"albendazole","Antifilarials","Oral > Solid > tablet: 400 mg (chewable, scored)","Filariasis","","Added","P02CA03","who.int"
"alcohol based hand rub","Disinfectants","Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol","Denatured alcohol","","Added","D08AX08","who.int"
"alcuronium","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 5 mg per  mL in 2 mL ampoule (alcuronium chloride)","Muscle relaxants","","Removed","M03AA01","who.int"
"all-trans retinoic acid","Targeted therapies","Oral > Solid: 10 mg capsule","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","L01XF01","who.int"
"allopurinol","Medicines used to treat gout","Oral > Solid: 100 mg","Gout","","Added","M04AA01","who.int"
"allopurinol","Supportive medicines","Oral > Solid: 100 mg; 300 mg","Tumour lysis syndrome","","Added","M04AA01","who.int"
"alteplase","Thrombolytic medicines","Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection","Cerebral ischaemic stroke","","Added","B01AD02","who.int"
"amidotrizoate","Diagnostic agents > Radiocontrast media","Parenteral > General injections > unspecified: 140 to 420 mg iodine per  mL in 20 mL ampoule (as sodium or meglumine salt)","Amidotrizoate","","Added","V08AA01","who.int"
"amikacin","Ophthalmological preparations > Anti-infective agents","","Other specified conjunctivitis","","Added","nan","who.int"
"amikacin","Ophthalmological preparations > Anti-infective agents","","Infectious blepharitis","","Added","nan","who.int"
"amikacin","Access group antibiotics","Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","Acute pyelonephritis (severe)","cefotaxime","Added","J01GB06","who.int"
"amikacin","Access group antibiotics","Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","Acute pyelonephritis (severe)","ceftriaxone","Added","J01GB06","who.int"
"amikacin","Access group antibiotics","Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","Sepsis without septic shock","cloxacillin","Added","J01GB06","who.int"
"amikacin","Antituberculosis medicines","Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01GB06","who.int"
"amiloride","Diuretics","Oral > Solid: 5 mg (hydrochloride)","Oedema","","Added","C03DB01","who.int"
"amiloride","Diuretics","Oral > Solid: 5 mg (hydrochloride)","Ascites","","Added","C03DB01","who.int"
"amiodarone","Antiarrhythmic medicines","Parenteral > General injections > IV: 50 mg per  mL in 3 ampoule (hydrochloride)
Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)","Cardiac arrhythmia","","Added","C01BD01","who.int"
"amitriptyline","Medicines for other common symptoms in palliative care","Oral > Solid: 25 mg; 10 mg; 75 mg","Palliative care","","Added","N06AA09","who.int"
"amlodipine","Antihypertensive medicines","Oral > Solid: 5 mg (as maleate, mesylate or besylate)","Essential hypertension","","Added","C08CA01","who.int"
"amodiaquine","Antimalarial medicines > For curative treatment","Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)","Malaria due to Plasmodium falciparum","","Added","P01BA06","who.int"
"amodiaquine","Antimalarial medicines > For curative treatment","Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)","Malaria due to Plasmodium vivax","","Added","P01BA06","who.int"
"amodiaquine + sulfadoxine + pyrimethamine","Antimalarial medicines > For chemoprevention","Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package","Malaria","","Added","P01BA06","who.int"
"amodiaquine + sulfadoxine + pyrimethamine","Antimalarial medicines > For chemoprevention","Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package","Malaria","","Added","P01BD51","who.int"
"amoxicillin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","Sepsis without septic shock","gentamicin","Added","J01CA04","who.int"
"amoxicillin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","Chronic obstructive pulmonary disease with acute exacerbation","","Added","J01CA04","who.int"
"amoxicillin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","Bacterial infection of unspecified site","","Removed","J01CA04","who.int"
"amoxicillin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection","Infectious cystitis","","Removed","J01CA04","who.int"
"amoxicillin + clavulanic acid","Access group antibiotics","Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
Oral > Solid: 500 mg + 125 mg tablet
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)","Chronic obstructive pulmonary disease with acute exacerbation","","Added","J01CR02","who.int"
"amoxicillin + clavulanic acid","Access group antibiotics","Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
Oral > Solid: 500 mg + 125 mg tablet
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)","Infectious cystitis","","Added","J01CR02","who.int"
"amoxicillin + clavulanic acid","Access group antibiotics","Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
Oral > Solid: 500 mg + 125 mg tablet
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)","Bacterial infection of unspecified site","","Removed","J01CR02","who.int"
"amoxicillin + clavulanic acid","Antituberculosis medicines","Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01CR02","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Blastomycosis","","Added","J02AA01","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Aspergillosis","","Added","J02AA01","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Cryptococcosis","","Added","J02AA01","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Candidosis","","Added","J02AA01","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Coccidioidomycosis","","Added","J02AA01","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Histoplasmosis","","Added","J02AA01","who.int"
"amphotericin b","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Sporotrichosis","","Added","J02AA01","who.int"
"amphotericin b","Antileishmaniasis medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)","Visceral leishmaniasis","","Added","J02AA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Acute malnutrition in infants, children or adolescents (complicated) [children]","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Peritonitis (mild-moderate)","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Peritonitis (severe)","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Peritoneal abscess (mild-moderate)","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Peritoneal abscess (severe)","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Sepsis without septic shock","gentamicin","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Bacterial meningitis","","Added","J01CA01","who.int"
"ampicillin","Access group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)","Bacterial infection of unspecified site","","Removed","J01CA01","who.int"
"anastrozole","Hormones and antihormones","Oral > Solid: 1 mg tablet","Other specified malignant neoplasms of breast","","Added","L02BG03","who.int"
"anastrozole","Hormones and antihormones","Oral > Solid: 1 mg tablet","Malignant neoplasms of breast","","Added","L02BG03","who.int"
"anidulafungin","Antifungal medicines","","Systemic or invasive candidosis","","Added","nan","who.int"
"ansuvimab","Medicines for Ebola virus disease","Parenteral > General injections > IV: 400 mg powder for injection","Ebola virus disease","","Added","J06BD04","who.int"
"anti-d immunoglobulin","Human immunoglobulins","Parenteral > General injections > IV: 250 µg in single-dose vial
Parenteral > General injections > IM: 250 µg in single-dose vial","Maternal care for red cell antibodies","","Added","J06BB01","who.int"
"anti-d immunoglobulin","Human immunoglobulins","Parenteral > General injections > IV: 250 µg in single-dose vial
Parenteral > General injections > IM: 250 µg in single-dose vial","Rh incompatibility reaction","","Added","J06BB01","who.int"
"anti-rabies immunoglobulin","Human immunoglobulins","Parenteral > General injections > IM: 150 IU per  mL in vial
Parenteral > Locoregional injections > Other: 150 IU per  mL in vial","Rabies","","Added","J06BB05","who.int"
"anti-rabies virus monoclonal antibodies","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > Locoregional injections > Intradermal: 40 IU per  mL in 1.25 mL vial (human); 40 IU per  mL in 2.5 mL vial (human); 100 IU per  mL in 2.5 mL vial (human); 300 IU per  mL in 10 mL vial (murine); 600 IU per  mL in 1 mL vial (murine); 600 IU per  mL in 2.5 mL vial (murine); 600 IU per  mL in 5 mL vial (murine)","Rabies","","Added","nan","who.int"
"anti-tetanus immunoglobulin","Human immunoglobulins","Parenteral > General injections > IM: 500 IU in vial","Tetanus","","Added","J06BB02","who.int"
"antirabies hyperimmune serum","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule","Rabies","","Removed","nan","who.int"
"antivenom immunoglobulin","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > General injections > IV: ","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","nan","who.int"
"antivenom sera","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > General injections > IV: ","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Removed","nan","who.int"
"apixaban","Medicines affecting coagulation","","Venous thromboembolism","","Added","nan","who.int"
"apixaban","Medicines affecting coagulation","","Other specified atrial fibrillation","","Added","nan","who.int"
"aprepitant","Antiemetic medicines","Oral > Liquid: 125 mg powder for oral suspension (in sachet)
Oral > Solid: 80 mg; 125 mg; 165 mg","Nausea or vomiting","","Added","A04AD12","who.int"
"arsenic trioxide","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg per  mL concentrate for solution for infusion; 2 mg per  mL concentrate for solution for infusion","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","L01XX27","who.int"
"artemether","Antimalarial medicines > For curative treatment","Parenteral > General injections > IM: 80 mg per  mL in 1 mL ampoule (oily injection)","Malaria due to Plasmodium falciparum","","Added","P01BE02","who.int"
"artemether","Antimalarial medicines > For curative treatment","Parenteral > General injections > IM: 80 mg per  mL in 1 mL ampoule (oily injection)","Malaria due to Plasmodium vivax","","Added","P01BE02","who.int"
"artemether + lumefantrine","Antimalarial medicines > For curative treatment","Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet","Malaria due to Plasmodium falciparum","","Added","P01BF01","who.int"
"artemether + lumefantrine","Antimalarial medicines > For curative treatment","Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet","Malaria due to Plasmodium vivax","","Added","P01BF01","who.int"
"artesunate","Antimalarial medicines > For curative treatment","Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
Oral > Solid: 50 mg tablet
Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules","Malaria due to Plasmodium falciparum","","Added","P01BE03","who.int"
"artesunate","Antimalarial medicines > For curative treatment","Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
Oral > Solid: 50 mg tablet
Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules","Malaria due to Plasmodium vivax","","Added","P01BE03","who.int"
"artesunate + amodiaquine","Antimalarial medicines > For curative treatment","Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet","Malaria due to Plasmodium falciparum","","Added","P01BF03","who.int"
"artesunate + amodiaquine","Antimalarial medicines > For curative treatment","Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet","Malaria due to Plasmodium vivax","","Added","P01BF03","who.int"
"artesunate + mefloquine","Antimalarial medicines > For curative treatment","Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet","Malaria due to Plasmodium falciparum","","Added","P01BF02","who.int"
"artesunate + mefloquine","Antimalarial medicines > For curative treatment","Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet","Malaria due to Plasmodium vivax","","Added","P01BF02","who.int"
"artesunate + pyronaridine tetraphosphate","Antimalarial medicines > For curative treatment","Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules","Malaria due to Plasmodium falciparum","","Added","P01BF06","who.int"
"artesunate + pyronaridine tetraphosphate","Antimalarial medicines > For curative treatment","Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules","Malaria due to Plasmodium vivax","","Added","P01BF06","who.int"
"ascorbic acid","Vitamins and minerals","Oral > Solid: 50 mg","Scurvy","","Added","A11GA01","who.int"
"asparaginase","Cytotoxic medicines","Powder for injection: 10 000 IU in vial.
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01XX02","who.int"
"asparaginase","Cytotoxic medicines","Powder for injection: 10 000 IU in vial.
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection","Lymphoid leukaemia, not elsewhere classified","","Added","L01XX02","who.int"
"atazanavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AE08","who.int"
"atazanavir + ritonavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR23","who.int"
"atenolol","Antianginal medicines","Oral > Solid: 50 mg; 100 mg","Angina pectoris","","Removed","C07AB03","who.int"
"atenolol","Antihypertensive medicines","Oral > Solid: 50 mg; 100 mg
","Essential hypertension","","Removed","C07AB03","who.int"
"atenolol","Antihypertensive medicines","Oral > Solid: 50 mg; 100 mg
","Essential hypertension","","Added","nan","who.int"
"atezolizumab","Immunomodulators","Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion","Other specified malignant neoplasms of bronchus or lung","","Removed","L01XC18","who.int"
"atoltivimab + maftivimab + odesivimab","Medicines for Ebola virus disease","Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial","Ebola virus disease","","Added","nan","who.int"
"atorvastatin","Lipid-lowering agents","","Mixed hyperlipidaemia","","Added","nan","who.int"
"atorvastatin","Lipid-lowering agents","","Coronary atherosclerosis","","Added","nan","who.int"
"atracurium","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 10 mg per  mL (besylate)","Muscle relaxants","","Added","M03AC04","who.int"
"atropine","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)","Exposure to or harmful effects of undetermined intent of pesticides","","Added","A03BA01","who.int"
"atropine","Preoperative medication and sedation for short-term procedures","Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)","Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics","","Added","A03BA01","who.int"
"atropine","Diagnostic agents > Ophthalmic medicines","","Cycloplegic drug","","Added","nan","who.int"
"atropine","Ophthalmological preparations > Mydriatics","Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)","Anterior uveitis","","Added","S01FA01","who.int"
"axicabtagene ciloleucel","Antineoplastics and supportive medicines","Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.","Diffuse large B-cell lymphomas","","Removed","L01XL03","who.int"
"azacitidine","Cytotoxic medicines","Parenteral > General injections > IV: 100 mg in vial powder for injection","Myeloid leukaemia","","Removed","L01BC07","who.int"
"azathioprine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 50 mg","Rheumatoid arthritis, serology unspecified","","Added","L04AX01","who.int"
"azathioprine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 50 mg","Psoriatic arthritis","","Added","L04AX01","who.int"
"azathioprine","Immunomodulators for non-malignant disease","Oral > Solid: 50 mg
Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 10 mg per  mL
Oral > Solid > tablet: 50 mg (scored); 25 mg","Relapsing-remitting multiple sclerosis","","Removed","L04AX01","who.int"
"azathioprine","Immunomodulators for non-malignant disease","Oral > Solid: 50 mg
Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 10 mg per  mL
Oral > Solid > tablet: 50 mg (scored); 25 mg","Failure or rejection of transplanted organs or tissues","","Added","L04AX01","who.int"
"azithromycin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 1.5% eye drops","Trachoma","","Added","S01AA26","who.int"
"azithromycin","Watch group antibiotics","Oral > Liquid: 200 mg per 5 mL oral liquid
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule","Gonococcal infection","ceftriaxone","Added","J01FA10","who.int"
"azithromycin","Watch group antibiotics","Oral > Liquid: 200 mg per 5 mL oral liquid
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule","Gonococcal infection","cefixime","Added","J01FA10","who.int"
"aztreonam","Reserve group antibiotics","Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection","Other specified bacterial diseases","","Removed","J01DF01","who.int"
"barium sulfate","Diagnostic agents > Radiocontrast media","Oral > Liquid: Aqueous suspension","Barium sulfate with suspending agents","","Added","V08BA01","who.int"
"beclometasone","Antiasthmatic and medicines for chronic obstructive pulmonary disease","
Respiratory > Inhalation > aerosol: 50 µg per  dose (dipropionate); 250 µg per  dose (dipropionatae)","Asthma","","Added","nan","who.int"
"beclometasone","Antiasthmatic and medicines for chronic obstructive pulmonary disease","
Respiratory > Inhalation > aerosol: 50 µg per  dose (dipropionate); 250 µg per  dose (dipropionatae)","Asthma","","Removed","R03BA01","who.int"
"beclometasone + formoterol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"bedaquiline","Antituberculosis medicines","Oral > Solid: 100 mg tablet; 20 mg tablet","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04AK05","who.int"
"bendamustine","Cytotoxic medicines","Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","L01AA09","who.int"
"bendamustine","Cytotoxic medicines","Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL","Follicular lymphoma","","Added","L01AA09","who.int"
"benzathine benzylpenicillin","Access group antibiotics","Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)","Congenital syphilis [children]","","Added","J01CE08","who.int"
"benzathine benzylpenicillin","Access group antibiotics","Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)","Syphilis","","Added","J01CE08","who.int"
"benzathine benzylpenicillin","Access group antibiotics","Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)","Bacterial infection of unspecified site","","Removed","J01CE08","who.int"
"benznidazole","American trypanosomiasis","Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg","Chagas disease","","Added","P01CA02","who.int"
"benzoic acid + salicylic acid","Dermatological medicines > Antifungal medicines","Local > Topical > Cream: 6% + 3%
Local > Topical > Ointment: 6% + 3%","Fungal infection of the skin","","Removed","nan","who.int"
"benzoyl peroxide","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Cream: 5%
Local > Topical > Lotion: 5%","Acne","","Added","D10AE01","who.int"
"benzyl benzoate","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 25%","Pthiriasis","","Added","P03AX01","who.int"
"benzyl benzoate","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 25%","Pediculosis corporis","","Added","P03AX01","who.int"
"benzyl benzoate","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 25%","Pediculosis capitis","","Added","P03AX01","who.int"
"benzyl benzoate","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 25%","Scabies","","Added","P03AX01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","gentamicin","Added","J01CE01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Congenital syphilis [children]","","Added","J01CE01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Syphilis","","Added","J01CE01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Acute malnutrition in infants, children or adolescents (complicated) [children]","gentamicin","Added","J01CE01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Sepsis without septic shock","gentamicin","Added","J01CE01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Bacterial meningitis","","Added","J01CE01","who.int"
"benzylpenicillin","Access group antibiotics","Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)","Bacterial infection of unspecified site","","Removed","J01CE01","who.int"
"betamethasone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)","Pruritus due to skin disorder","","Added","D07AC01","who.int"
"betamethasone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)","Psoriasis of unspecified type","","Added","D07AC01","who.int"
"betamethasone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)","Dermatitis or eczema","","Added","D07AC01","who.int"
"betamethasone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)","Lichen planus","","Added","D07AC01","who.int"
"bevacizumab","Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations","Parenteral > Locoregional injections > Intravitreal: 25 mg per  mL","Age related macular degeneration","","Added","S01LA08","who.int"
"bicalutamide","Hormones and antihormones","Oral > Solid: 50 mg","Malignant neoplasms of prostate","","Added","L02BB03","who.int"
"binimetinib","Targeted therapies","","Other specified melanoma of skin","","Removed","nan","who.int"
"biperiden","Medicines for parkinsonism","Parenteral > General injections > IV: 5 mg per  mL in 1 mL ampoule (lactate)
Oral > Solid: 2 mg tablet (hydrochloride)","Parkinson disease","","Added","N04AA02","who.int"
"bisacodyl","Laxatives","","Constipation","","Added","nan","who.int"
"bisoprolol","Antianginal medicines","Oral > Solid: 1.25 mg; 5 mg","Angina pectoris","","Added","C07AB07","who.int"
"bisoprolol","Medicines used in heart failure","Oral > Solid: 1.25 mg; 5 mg","Heart failure","","Added","C07AB07","who.int"
"bisoprolol","Antihypertensive medicines","Oral > Solid: 1.25 mg; 5 mg","Essential hypertension","","Added","C07AB07","who.int"
"bisoprolol","Antiarrhythmic medicines","Oral > Solid: 1.25 mg; 5 mg","Cardiac arrhythmia","","Added","C07AB07","who.int"
"bleomycin","Cytotoxic medicines","Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01DC01","who.int"
"bleomycin","Cytotoxic medicines","Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","Kaposi sarcoma of unspecified primary site","","Added","L01DC01","who.int"
"bleomycin","Cytotoxic medicines","Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","Hodgkin lymphoma","","Added","L01DC01","who.int"
"bleomycin","Cytotoxic medicines","Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","Other specified malignant neoplasms of the ovary","","Added","L01DC01","who.int"
"bleomycin","Cytotoxic medicines","Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)","Germ cell tumour of testis","","Added","L01DC01","who.int"
"bortezomib","Targeted therapies","Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection","Plasma cell myeloma","","Added","L01XG01","who.int"
"bromocriptine","Antiseizure medicines","Oral > Solid: 2.5 mg; 5 mg","Parkinson disease","","Removed","N04BC01","who.int"
"budesonide","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Respiratory > Inhalation > aerosol: 100 µg per  dose; 200 µg per  dose","Asthma","","Added","R03BA02","who.int"
"budesonide","Ear, nose and throat medicines [c]","Local > Nasal > Spray: 100 µg per  dose","Allergic rhinitis","","Added","R01AD05","who.int"
"budesonide + formoterol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose","Asthma","","Added","R03AK07","who.int"
"budesonide + salmeterol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"bumetanide","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"bumetanide","Diuretics","","Anuria or oliguria","","Added","nan","who.int"
"bumetanide","Diuretics","","Oedema","","Added","nan","who.int"
"bupivacaine","Local anaesthetics","Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)","Local anaesthetics","","Added","N01BB01","who.int"
"buprenorphine","Medicines for opioid use disorders","","Opioid dependence","","Added","nan","who.int"
"bupropion","Medicines for nicotine use disorders","Oral > Solid: 150 mg sustained-release (hydrochloride)","Nicotine dependence","","Added","N06AX12","who.int"
"c1 esterase inhibitor","Plasma-derived medicines","Parenteral > General injections > IV: 500 IU in vial powder for injection","Hereditary angioedema","","Removed","nan","who.int"
"cabergoline","Antiseizure medicines","Oral > Solid: 0.5 mg","Parkinson disease","","Removed","N04BC06","who.int"
"caffeine citrate","Medicines administered to the neonate [c]","Parenteral > General injections > IV: 20 mg per  mL (equivalent to 10 mg caffeine base per mL)
Oral > Liquid: 20 mg per  mL (equivalent to 10 mg caffeine base per mL)","Apnoea of newborn","","Added","N06BC01","who.int"
"calamine","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Lotion: ","Pruritus","","Added","D02AB","who.int"
"calcipotriol","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Cream: 50 µg per  mL (0.005%)
Local > Topical > Lotion: 50 µg per  mL (0.005%)
Local > Topical > Ointment: 50 µg per  mL (0.005%)","Psoriasis of unspecified type","","Added","D05AX02","who.int"
"calcitriol","Dermatological medicines > Medicines affecting skin differentiation and proliferation","","Psoriasis of unspecified type","","Added","nan","who.int"
"calcium","Vitamins and minerals","Oral > Solid: 500 mg (elemental calcium)","Calcium deficiency","","Added","A12AA20","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","V03AF03","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Malignant neoplasm metastasis in large intestine","","Added","V03AF03","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Malignant trophoblastic neoplasms of placenta","","Added","V03AF03","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Burkitt lymphoma including Burkitt leukaemia","","Added","V03AF03","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","V03AF03","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Malignant neoplasms of rectum","","Added","V03AF03","who.int"
"calcium folinate (leucovorin calcium)","Cytotoxic medicines","Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg","Malignant neoplasms of colon","","Added","V03AF03","who.int"
"calcium gluconate","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","Hypermagnesaemia","","Added","A12AA03","who.int"
"calcium gluconate","Vitamins and minerals","Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","Tetany due to acute calcium deficiency","","Added","A12AA03","who.int"
"canagliflozin","Oral hypoglycaemic agents","","Type 2 diabetes mellitus","","Added","nan","who.int"
"capecitabine","Cytotoxic medicines","Oral > Solid: 150 mg tablet; 500 mg tablet","Malignant neoplasms of colon","","Added","L01BC06","who.int"
"capecitabine","Cytotoxic medicines","Oral > Solid: 150 mg tablet; 500 mg tablet","Other specified malignant neoplasms of breast","","Added","L01BC06","who.int"
"capecitabine","Cytotoxic medicines","Oral > Solid: 150 mg tablet; 500 mg tablet","Malignant neoplasm metastasis in large intestine","","Added","L01BC06","who.int"
"capecitabine","Cytotoxic medicines","Oral > Solid: 150 mg tablet; 500 mg tablet","Malignant neoplasms of rectum","","Added","L01BC06","who.int"
"capreomycin","Antituberculosis medicines","Parenteral > General injections > IV: 1000 mg powder for injection (vial)","Multi-drug resistant Mycobacterium tuberculosis","","Removed","J04AB30","who.int"
"captopril","Medicines used in heart failure","Oral > Solid: 25 mg","Heart failure","","Removed","C09AA01","who.int"
"carbachol","Ophthalmological preparations > Miotics and antiglaucoma medicines","","Acute angle closure with pupillary block","","Added","nan","who.int"
"carbachol","Ophthalmological preparations > Miotics and antiglaucoma medicines","","Ocular hypertension","","Added","nan","who.int"
"carbachol","Ophthalmological preparations > Miotics and antiglaucoma medicines","","Primary open-angle glaucoma","","Added","nan","who.int"
"carbamazepine","Antiseizure medicines","Oral > Liquid: 100 mg per 5 mL
Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)","Epilepsy or seizures","","Added","N03AF01","who.int"
"carbamazepine","Medicines for bipolar disorders","Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg","Bipolar or related disorders","","Added","N03AF01","who.int"
"carbetocin","Uterotonics","Parenteral > General injections > IV: 100 µg per  mL (heat stable)","Postpartum haemorrhage","","Added","H01BB03","who.int"
"carbimazole","Thyroid hormones and antithyroid medicines","","Thyrotoxicosis","","Added","nan","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Other specified gliomas of brain","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Other specified carcinomas of ovary","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Retinoblastoma","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Other specified malignant neoplasms of bronchus or lung","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Malignant neoplasms of nasopharynx","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Malignant neoplasms of kidney, except renal pelvis","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Malignant neoplasms of breast","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Malignant neoplasms of lip, oral cavity or pharynx","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Malignant neoplasms of cervix uteri","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Other specified malignant neoplasms of the ovary","","Added","L01XA02","who.int"
"carboplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL","Germ cell tumour of testis","","Added","L01XA02","who.int"
"carvedilol","Antianginal medicines","","Angina pectoris","","Added","nan","who.int"
"carvedilol","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"carvedilol","Antihypertensive medicines","","Essential hypertension","","Added","nan","who.int"
"carvedilol","Antiarrhythmic medicines","","Cardiac arrhythmia","","Added","nan","who.int"
"caspofungin","Antifungal medicines","","Systemic or invasive candidosis","","Added","nan","who.int"
"cefalexin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (as monohydrate)
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)","Chronic obstructive pulmonary disease with acute exacerbation","","Added","J01DB01","who.int"
"cefalexin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (as monohydrate)
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)","Bacterial infection of unspecified site","","Removed","J01DB01","who.int"
"cefazolin","Access group antibiotics","Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","Other specified prophylactic measures","metronidazole","Added","J01DB04","who.int"
"cefazolin","Access group antibiotics","Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","Other specified prophylactic measures","","Added","J01DB04","who.int"
"cefazolin","Access group antibiotics","Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","Bacterial infection of joint","","Added","J01DB04","who.int"
"cefazolin","Access group antibiotics","Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","Osteomyelitis or osteitis","","Added","J01DB04","who.int"
"cefazolin","Access group antibiotics","Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection","Surgical site infection","","Removed","J01DB04","who.int"
"cefepime","Watch group antibiotics","Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection","Other specified bacterial diseases","","Removed","J01DE01","who.int"
"cefixime","Watch group antibiotics","Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)","Infectious gastroenteritis or colitis without specification of infectious agent","","Added","J01DD08","who.int"
"cefixime","Watch group antibiotics","Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)","Gonococcal infection","azithromycin","Added","J01DD08","who.int"
"cefotaxime","Watch group antibiotics","Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)","Bacterial infection of unspecified site","","Removed","J01DD01","who.int"
"ceftaroline","Reserve group antibiotics","Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection","Other specified bacterial diseases","","Removed","J01DI02","who.int"
"ceftazidime","Watch group antibiotics","Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection","Endophthalmitis","vancomycin","Added","J01DD02","who.int"
"ceftazidime","Watch group antibiotics","Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection","Pseudomonas aeruginosa resistant to other antibiotic","","Added","J01DD02","who.int"
"ceftazidime + avibactam","Reserve group antibiotics","Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection","Carbapenem-resistant Pseudomonas aeruginosa","","Added","J01DD52","who.int"
"ceftazidime + avibactam","Reserve group antibiotics","Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection","Carbapenem resistant Enterobacterales","","Added","J01DD52","who.int"
"ceftolozane + tazobactam","Reserve group antibiotics","Parenteral > General injections > IV: 1 g + 0.5 g powder for injection","Carbapenem-resistant Pseudomonas aeruginosa","","Added","J01DI54","who.int"
"ceftriaxone","Watch group antibiotics","Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)","Necrotising fasciitis","metronidazole","Added","J01DD04","who.int"
"ceftriaxone","Watch group antibiotics","Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)","Bacterial infection of unspecified site","","Removed","J01DD04","who.int"
"cefuroxime","Watch group antibiotics","Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection","Other specified prophylactic measures","","Added","J01DC02","who.int"
"certolizumab pegol","Immunomodulators for non-malignant disease","","Axial spondyloarthritis","","Added","nan","who.int"
"certolizumab pegol","Immunomodulators for non-malignant disease","","Crohn disease site","","Added","nan","who.int"
"certolizumab pegol","Immunomodulators for non-malignant disease","","Rheumatoid arthritis","","Added","nan","who.int"
"certolizumab pegol","Medicines for juvenile joint diseases","","Juvenile idiopathic arthritis","","Added","nan","who.int"
"cetirizine","Antiallergics and medicines used in anaphylaxis","","Allergic or hypersensitivity conditions of unspecified type","","Added","nan","who.int"
"chlorambucil","Cytotoxic medicines","Oral > Solid: 2 mg tablet","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01AA02","who.int"
"chlorambucil","Cytotoxic medicines","Oral > Solid: 2 mg tablet","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","L01AA02","who.int"
"chloramphenicol","Access group antibiotics","Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
Oral > Liquid: 150 mg per 5 mL (as palmitate)
Oral > Solid: 250 mg capsule","Bacterial infection of unspecified site","","Removed","J01BA01","who.int"
"chlorhexidine","Medicines administered to the neonate [c]","Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)","Omphalitis of newborn","","Added","D08AC02","who.int"
"chlorhexidine","Antiseptics","Local > Topical > Solution: 5% (digluconate) for dilution","Chlorhexidine","","Added","D08AC02","who.int"
"chlorine base compound","Disinfectants","Local > Topical > Powder: 0.1% available chlorine for solution
Local > Topical > Liquid: 0.1% available chlorine for solution
Local > Topical > Solid: 0.1% available chlorine for solution","Disinfectant, not elsewhere classified","","Added","nan","who.int"
"chloroquine","Antimalarial medicines > For chemoprevention","Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)","Malaria due to Plasmodium falciparum","","Removed","P01BA01","who.int"
"chloroquine","Antimalarial medicines > For chemoprevention","Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)","Malaria due to Plasmodium vivax","","Added","P01BA01","who.int"
"chloroquine","Antimalarial medicines > For chemoprevention","Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)","Malaria due to Plasmodium ovale","","Added","P01BA01","who.int"
"chloroquine","Antimalarial medicines > For chemoprevention","Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)","Malaria due to Plasmodium malariae","","Added","P01BA01","who.int"
"chloroquine","Antimalarial medicines > For curative treatment","Parenteral > General injections > IV: 40 mg per  mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)","Malaria due to Plasmodium falciparum","","Removed","P01BA01","who.int"
"chloroquine","Antimalarial medicines > For curative treatment","Parenteral > General injections > IV: 40 mg per  mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)","Malaria due to Plasmodium vivax","","Added","P01BA01","who.int"
"chloroquine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)","Rheumatoid arthritis","","Added","P01BA01","who.int"
"chlorothiazide","Antihypertensive medicines","","Essential hypertension","","Added","nan","who.int"
"chlorothiazide","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"chloroxylenol","Disinfectants","Local > Topical > Solution: 4.8%","Phenol disinfectant, not elsewhere classified","","Added","D08AE05","who.int"
"chlortalidone","Antihypertensive medicines","","Essential hypertension","","Added","nan","who.int"
"chlortalidone","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"chlortetracycline","Ophthalmological preparations > Anti-infective agents","","Other specified conjunctivitis","","Added","nan","who.int"
"chlortetracycline","Ophthalmological preparations > Anti-infective agents","","Infectious keratitis","","Added","nan","who.int"
"chlortetracycline","Ophthalmological preparations > Anti-infective agents","","Infectious blepharitis","","Added","nan","who.int"
"chlortetracycline","Ophthalmological preparations > Anti-infective agents","","Trachoma","","Added","nan","who.int"
"cholera vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against cholera alone","","Added","J07AE01","who.int"
"ciclesonide","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"ciclosporin","Immunomodulators for non-malignant disease","Parenteral > General injections > IV: 50 mg per  mL in 1 mL ampoule concentrate for injection
Oral > Liquid: 100 mg per  mL
Oral > Solid > capsule: 25 mg","Failure or rejection of transplanted organs or tissues","","Added","L04AD01","who.int"
"cimetidine","Antiulcer medicines","Oral > Solid: 200 mg
Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule","Peptic ulcer, site unspecified","","Removed","A02BA01","who.int"
"cimetidine","Antiulcer medicines","Oral > Solid: 200 mg
Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule","Gastro-oesophageal reflux disease","","Removed","A02BA01","who.int"
"ciprofloxacin","Watch group antibiotics","Parenteral > General injections > IV: 2 mg per  mL (as hyclate)
Oral > Liquid: 250 mg per 5 mL (anhydrous)
Oral > Solid: 250 mg (as hydrochloride)
Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)","Inflammatory and other diseases of prostate (mild to moderate)","","Added","J01MA02","who.int"
"ciprofloxacin","Watch group antibiotics","Parenteral > General injections > IV: 2 mg per  mL (as hyclate)
Oral > Liquid: 250 mg per 5 mL (anhydrous)
Oral > Solid: 250 mg (as hydrochloride)
Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)","Bacterial infection of unspecified site","","Removed","J01MA02","who.int"
"ciprofloxacin","Ear, nose and throat medicines [c]","Local > Otological > drops: 0.3% (as hydrochloride)","Infectious diseases of external ear","","Added","S02AA15","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Other specified gliomas of brain","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Other specified malignant neoplasms of the ovary","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Other specified malignant neoplasms of bronchus or lung","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Malignant neoplasms of nasopharynx","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Germ cell tumour of testis","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Malignant neoplasms of lip, oral cavity or pharynx","","Added","L01XA01","who.int"
"cisplatin","Cytotoxic medicines","Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL","Malignant neoplasms of cervix uteri","","Added","L01XA01","who.int"
"cladribine","Medicines for multiple sclerosis","Oral > Solid > tablet: 10 mg","Multiple sclerosis","","Added","L04AA40","who.int"
"cladribine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg per  mL in 10 mL vial; 2 mg per  mL in 5 mL vial","Langerhans cell histiocytosis","","Removed","L01BB04","who.int"
"clindamycin","Access group antibiotics","Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
Oral > Solid: 150 mg (as hydrochloride) capsule
Parenteral > General injections > unspecified: 150 mg per  mL (as phosphate) injection","Bacterial infection of unspecified site","","Removed","J01FF01","who.int"
"clofazimine","Antituberculosis medicines","Oral > Solid: 100 mg; 50 mg","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04BA01","who.int"
"clofazimine","Antileprosy medicines","Oral > Solid: 100 mg; 50 mg","Leprosy","","Added","J04BA01","who.int"
"clomifene","Ovulation inducers","Oral > Solid: 50 mg (citrate)","Female infertility without specification whether primary or secondary","","Added","G03GB02","who.int"
"clomipramine","Medicines for obsessive compulsive disorders","Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)","Obsessive-compulsive disorder","","Added","N06AA04","who.int"
"clonazepam","Antiseizure medicines","Oral > Solid: 500 µg","Generalised myoclonic seizure","","Removed","N03AE01","who.int"
"clopidogrel","Anti-platelet medicines","Oral > Solid: 75 mg; 300 mg","Acute ischaemic heart disease","","Added","B01AC04","who.int"
"clopidogrel","Anti-platelet medicines","Oral > Solid: 75 mg; 300 mg","Presence of coronary angioplasty implant or graft","","Added","B01AC04","who.int"
"clotrimazole","Antifungal medicines","Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet","Vulvovaginal candidosis","","Added","G01AF02","who.int"
"cloxacillin","Access group antibiotics","Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection","Bacterial infection of unspecified site","","Removed","J01CF02","who.int"
"clozapine","Medicines for psychotic disorders","Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg","Schizophrenia or other primary psychotic disorders","","Added","N05AH02","who.int"
"coal tar","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Solution: 5%","Psoriasis of unspecified type","","Added","D05AA","who.int"
"cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate","Fixed-dose combinations of antiretrovirals","Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AR09","who.int"
"cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide","Fixed-dose combinations of antiretrovirals","Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AR18","who.int"
"cobimetinib","Targeted therapies","","Other specified melanoma of skin","","Removed","nan","who.int"
"codeine","Opioid analgesics","Oral > Solid: 30 mg tablet (codeine phosphate)","Pain","","Added","nan","who.int"
"codeine","Antitussives","Oral > Solid: 10 mg tablet (codeine phosphate)","Cough","","Removed","R05DA04","who.int"
"codeine","Medicines for diarrhoea","Oral > Solid: 30 mg tablet (codeine phosphate)","Diarrhoea","","Removed","nan","who.int"
"colchicine","Medicines used to treat gout","Oral > Solid: 0.5 mg","Gout","","Removed","M04AC01","who.int"
"colecalciferol","Vitamins and minerals","Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
","Calcium deficiency","","Added","A11CC05","who.int"
"colecalciferol","Vitamins and minerals","Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
","Vitamin D deficiency","","Added","A11CC05","who.int"
"colecalciferol","Vitamins and minerals","Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
","Vitamin D deficiency","","Added","nan","who.int"
"colecalciferol","Vitamins and minerals","Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
","Calcium deficiency","","Added","nan","who.int"
"colistin (injection)","Reserve group antibiotics","Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)","Other specified bacterial diseases","","Removed","J01XB01","who.int"
"compound sodium lactate solution","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: injectable solution","Other specified disorders of fluid, electrolyte or acid-base balance","","Added","nan","who.int"
"compound sodium lactate solution","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: injectable solution","Hypovolaemic shock","","Added","nan","who.int"
"condoms","Barrier methods","-","Contact with health services for contraceptive management","","Added","nan","who.int"
"copper-containing intrauterine device","Intrauterine devices","-","Contact with health services for insertion of contraceptive device","","Added","G02BA02","who.int"
"crizotinib","Targeted therapies","Oral > Solid: 200 mg; 250 mg
Oral > Solid > capsule: 200 mg; 250 mg","Other specified malignant neoplasms of bronchus or lung","","Removed","L01ED01","who.int"
"crizotinib","Targeted therapies","Oral > Solid: 200 mg; 250 mg
Oral > Solid > capsule: 200 mg; 250 mg","Anaplastic large cell lymphoma, ALK-positive","","Removed","L01ED01","who.int"
"cyanocobalamin","Antianaemia medicines",".","Anaemias or other erythrocyte disorders","","Removed","B03BA01","who.int"
"cyclizine","Medicines for other common symptoms in palliative care","Oral > Solid: 50 mg tablet
Parenteral > General injections > unspecified: 50 mg per  mL","Palliative care","","Added","R06AE03","who.int"
"cyclopentolate","Diagnostic agents > Ophthalmic medicines","","Cycloplegic drug","","Added","nan","who.int"
"cyclopentolate","Ophthalmological preparations > Mydriatics","","Anterior uveitis","","Added","nan","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Burkitt lymphoma including Burkitt leukaemia","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Malignant neoplasms of breast","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Lymphoid leukaemia, not elsewhere classified","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Diffuse large B-cell lymphomas","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Plasma cell myeloma","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Other specified gliomas of brain","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Other specified malignant neoplasms of breast","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Malignant trophoblastic neoplasms of placenta","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Follicular lymphoma","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Malignant neoplasms of kidney, except renal pelvis","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Rhabdomyosarcoma primary site","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Hodgkin lymphoma","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Anaplastic large cell lymphoma, ALK-negative","","Added","L01AA01","who.int"
"cyclophosphamide","Cytotoxic medicines","Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet","Anaplastic large cell lymphoma, ALK-positive","","Added","L01AA01","who.int"
"cycloserine","Antituberculosis medicines","Oral > Solid: 250 mg; 125 mg","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04AB01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Lymphoid leukaemia, not elsewhere classified","","Added","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Myeloid leukaemia","","Added","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Burkitt lymphoma including Burkitt leukaemia","","Added","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Anaplastic large cell lymphoma, ALK-negative","","Added","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Anaplastic large cell lymphoma, ALK-positive","","Added","L01BC01","who.int"
"cytarabine","Cytotoxic medicines","Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial","Langerhans cell histiocytosis","","Added","L01BC01","who.int"
"dabigatran","Medicines affecting coagulation","Oral > Solid: 110 mg; 150 mg","Venous thromboembolism","","Added","B01AE07","who.int"
"dabigatran","Medicines affecting coagulation","Oral > Solid: 110 mg; 150 mg","Other specified atrial fibrillation","","Added","B01AE07","who.int"
"dabrafenib","Targeted therapies","Oral > Solid: 50 mg; 75 mg","Other specified melanoma of skin","","Removed","L01EC02","who.int"
"dacarbazine","Cytotoxic medicines","Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection","Hodgkin lymphoma","","Added","L01AX04","who.int"
"daclatasvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)","Chronic hepatitis C","","Added","J05AP07","who.int"
"daclatasvir + sofosbuvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid: 60 mg + 400 mg","Chronic hepatitis C","","Added","J05AP07","who.int"
"daclatasvir + sofosbuvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid: 60 mg + 400 mg","Chronic hepatitis C","","Added","J05AP08","who.int"
"dactinomycin","Cytotoxic medicines","Parenteral > General injections > IV: 500 µg in vial powder for injection","Malignant trophoblastic neoplasms of placenta","","Added","L01DA01","who.int"
"dactinomycin","Cytotoxic medicines","Parenteral > General injections > IV: 500 µg in vial powder for injection","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01DA01","who.int"
"dactinomycin","Cytotoxic medicines","Parenteral > General injections > IV: 500 µg in vial powder for injection","Malignant neoplasms of kidney, except renal pelvis","","Added","L01DA01","who.int"
"dactinomycin","Cytotoxic medicines","Parenteral > General injections > IV: 500 µg in vial powder for injection","Rhabdomyosarcoma primary site","","Added","L01DA01","who.int"
"dactinomycin","Cytotoxic medicines","Parenteral > General injections > IV: 500 µg in vial powder for injection","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","L01DA01","who.int"
"dalteparin","Medicines affecting coagulation","","Acute ischaemic heart disease","","Added","nan","who.int"
"dalteparin","Medicines affecting coagulation","","Venous thromboembolism","","Added","nan","who.int"
"dapagliflozin","Oral hypoglycaemic agents","","Type 2 diabetes mellitus","","Added","nan","who.int"
"dapsone","Antileprosy medicines","Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet","Leprosy","","Added","J04BA02","who.int"
"daptomycin","Reserve group antibiotics","Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection","Other specified bacterial diseases","","Removed","J01XX09","who.int"
"daratumumab","Immunomodulators","Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL","Plasma cell myeloma","","Removed","L01FC01","who.int"
"darbepoetin alfa","Antianaemia medicines","","Anaemia due to chronic disease","","Added","nan","who.int"
"darunavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AE10","who.int"
"dasabuvir","Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","Oral > Solid: 250 mg tablet","Chronic hepatitis C","","Removed","J05AX16","who.int"
"dasatinib","Targeted therapies","Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet","Chronic myeloid leukaemia, not elsewhere classified","","Added","L01EA02","who.int"
"daunorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)","Lymphoid leukaemia, not elsewhere classified","","Added","L01DB02","who.int"
"daunorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)","Myeloid leukaemia","","Added","L01DB02","who.int"
"daunorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","L01DB02","who.int"
"deferoxamine","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)","Harmful effects of drugs, medicaments or biological substances, not elsewhere classified","","Added","V03AC01","who.int"
"delafloxacin","Watch group antibiotics","Parenteral > General injections > IV: 300 mg lyophilized powder for injection
Oral > Solid: 450 mg","Methicillin resistant Staphylococcus aureus","","Removed","J01MA23","who.int"
"delamanid","Antituberculosis medicines","Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04AK06","who.int"
"dengue vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BX04","who.int"
"desmopressin","Medicines affecting coagulation","Parenteral > General injections > IV: 4 µg per  mL in 1 mL ampoule (acetate)
Local > Nasal > Spray: 10 µg per  dose (acetate)","Haemophilia A","","Added","H01BA02","who.int"
"desmopressin","Medicines affecting coagulation","Parenteral > General injections > IV: 4 µg per  mL in 1 mL ampoule (acetate)
Local > Nasal > Spray: 10 µg per  dose (acetate)","Von Willebrand disease","","Added","H01BA02","who.int"
"dexamethasone","Other medicines administered to the mother","Parenteral > General injections > unspecified: 4 mg per  mL (dexamethasone phosphate (as sodium))","Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy","","Added","H02AB02","who.int"
"dexamethasone","Hormones and antihormones","Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg","Plasma cell myeloma","","Added","L01AA01","who.int"
"dexamethasone","Hormones and antihormones","Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg","Lymphoid leukaemia, not elsewhere classified","","Added","H02AB02","who.int"
"dexamethasone","Hormones and antihormones","Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg","Burkitt lymphoma including Burkitt leukaemia","","Added","H02AB02","who.int"
"dexamethasone","Hormones and antihormones","Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg","Anaplastic large cell lymphoma, ALK-negative","","Added","H02AB02","who.int"
"dexamethasone","Hormones and antihormones","Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg","Anaplastic large cell lymphoma, ALK-positive","","Added","H02AB02","who.int"
"dexamethasone","Antiallergics and medicines used in anaphylaxis","Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)","Allergic or hypersensitivity conditions of unspecified type","","Added","H02AB02","who.int"
"dexamethasone","Medicines for other common symptoms in palliative care","Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)","Palliative care","","Added","C05AA09","who.int"
"dexamethasone","Antiemetic medicines","Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)","Nausea or vomiting","","Added","H02AB02","who.int"
"dextran 40","Plasma substitutes",".","Hypovolaemia","","Removed","B05AA05","who.int"
"dextran 70","Plasma substitutes","Parenteral > General injections > IV: 6% injectable solution","Hypovolaemia","","Added","B05AA05","who.int"
"diaphragms","Barrier methods","-","Contact with health services for contraceptive management","","Added","nan","who.int"
"diazepam","Antiseizure medicines","
Local > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system
Local > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube","Status epilepticus","","Added","nan","who.int"
"diazepam","Antiseizure medicines","
Local > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system
Local > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube","Status epilepticus","","Added","N05BA01","who.int"
"diazepam","Medicines for other common symptoms in palliative care","Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 5 mg; 10 mg
Local > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system
Local > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube
Parenteral > General injections > unspecified: 5 mg per  mL","Palliative care","","Added","N05BA01","who.int"
"diazoxide","Medicines for hypoglycaemia","Oral > Liquid: 50 mg per  mL
Oral > Solid: 50 mg","Persistent hyperinsulinaemic hypoglycaemia of infancy","","Added","V03AH01","who.int"
"didanosine","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AF02","who.int"
"diethylcarbamazine","Antifilarials","Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)","Lymphatic filariasis","","Added","P02CB02","who.int"
"digitoxin","Medicines used in heart failure","Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
Oral > Solid: 50 µg; 100 µg","Heart failure","","Removed","C01AA04","who.int"
"digoxin","Antiarrhythmic medicines","Parenteral > General injections > IV: 250 µg per  mL in 2 mL ampoule
Oral > Liquid: 50 µg per  mL
Oral > Solid: 62.5 µg; 250 µg","Cardiac arrhythmia","","Added","C01AA05","who.int"
"digoxin","Medicines used in heart failure","Parenteral > General injections > IV: 250 µg per  mL in 2 mL ampoule; 100 µg per  mL in 1 mL ampoule
Oral > Liquid: 50 µg per  mL
Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg","Heart failure","","Added","C01AA05","who.int"
"dihydroartemisinin + piperaquine phosphate","Antimalarial medicines > For curative treatment","Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet","Malaria due to Plasmodium falciparum","","Added","P01BF05","who.int"
"dihydroartemisinin + piperaquine phosphate","Antimalarial medicines > For curative treatment","Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet","Malaria due to Plasmodium vivax","","Added","P01BF05","who.int"
"dihydroergocryptine mesylate","Antiseizure medicines","Oral > Solid: ","Parkinson disease","","Removed","N04BC03","who.int"
"diloxanide","Antiamoebic and antigiardiasis medicines","Oral > Solid: 500 mg (furoate)","Amoebiasis","","Added","P01AC01","who.int"
"dimercaprol","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IM: 50 mg per  mL in 2 mL ampoule","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","V03AB09","who.int"
"diphtheria antitoxin","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial","Need for immunization against diphtheria alone","","Added","J06AA01","who.int"
"diphtheria vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against diphtheria alone","","Added","J07AF01","who.int"
"diphtheria-pertussis-tetanus vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against diphtheria-tetanus-pertussis, combined","","Removed","J07AJ52","who.int"
"diphtheria-tetanus vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against combinations of infectious diseases","","Removed","J07AM51","who.int"
"docetaxel","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","Other specified malignant neoplasms of breast","","Added","L01CD02","who.int"
"docetaxel","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","Malignant neoplasms of breast","","Added","L01CD02","who.int"
"docetaxel","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","Malignant neoplasms of prostate","","Added","L01CD02","who.int"
"docetaxel","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01CD02","who.int"
"docusate sodium","Medicines for other common symptoms in palliative care","Oral > Liquid: 50 mg per 5 mL oral liquid
Oral > Solid: 100 mg capsule","Palliative care","","Added","A06AA02","who.int"
"dolasetron","Medicines for other common symptoms in palliative care","","Palliative care","","Added","nan","who.int"
"dolasetron","Antiemetic medicines","","Nausea or vomiting","","Added","nan","who.int"
"dolutegravir","Antiretrovirals > Integrase inhibitors","Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AJ03","who.int"
"dolutegravir + lamivudine + tenofovir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR27","who.int"
"donepezil","Medicines for diseases of the nervous system","Oral > Liquid: 1 mg per  mL (hydrochloride)
Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)","Dementia due to Alzheimer disease","","Removed","N06DA02","who.int"
"dopamine","Medicines used in heart failure","Parenteral > General injections > IV: 40 mg per  mL in 5 mL vial (hydrochloride)","Heart failure","","Added","C01CA04","who.int"
"dopamine","Medicines used in heart failure","Parenteral > General injections > IV: 40 mg per  mL in 5 mL vial (hydrochloride)","Cardiogenic shock","","Added","C01CA04","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Rhabdomyosarcoma primary site","","Removed","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Follicular lymphoma","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Burkitt lymphoma including Burkitt leukaemia","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Malignant neoplasms of breast","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Lymphoid leukaemia, not elsewhere classified","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Other specified malignant neoplasms of breast","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Diffuse large B-cell lymphomas","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Plasma cell myeloma","","Added","L01AA01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Malignant neoplasms of kidney, except renal pelvis","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Kaposi sarcoma of unspecified primary site","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Hodgkin lymphoma","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Anaplastic large cell lymphoma, ALK-negative","","Added","L01DB01","who.int"
"doxorubicin","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)","Anaplastic large cell lymphoma, ALK-positive","","Added","L01DB01","who.int"
"doxycycline","Access group antibiotics","Oral > Solid: 100 mg (as hyclate)
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)","Chlamydia trachomatis","","Added","J01AA02","who.int"
"doxycycline","Access group antibiotics","Oral > Solid: 100 mg (as hyclate)
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)","Chronic obstructive pulmonary disease with acute exacerbation","","Added","J01AA02","who.int"
"doxycycline","Access group antibiotics","Oral > Solid: 100 mg (as hyclate)
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)","Bacterial infection of unspecified site","","Removed","J01AA02","who.int"
"doxycycline","Antimalarial medicines > For curative treatment","Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)","Malaria due to Plasmodium falciparum","","Added","J01AA02","who.int"
"doxycycline","Antimalarial medicines > For chemoprevention","Oral > Solid: 100 mg (hydrochloride or hyclate)","Malaria due to Plasmodium falciparum","","Added","J01AA02","who.int"
"edoxaban","Medicines affecting coagulation","","Venous thromboembolism","","Added","nan","who.int"
"edoxaban","Medicines affecting coagulation","","Other specified atrial fibrillation","","Added","nan","who.int"
"efavirenz","Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors","Oral > Solid: 600 mg tablet","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AG03","who.int"
"efavirenz + emtricitabine + tenofovir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR06","who.int"
"efavirenz + lamivudine + tenofovir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR11","who.int"
"efavirenz + lamivudine + tenofovir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","nan","who.int"
"eflornithine","Medicines for the treatment of 2nd stage African trypanosomiasis","Parenteral > General injections > IV: 200 mg per  mL in 50 mL bottle (hydrochloride)","African trypanosomiasis","","Added","P01CX03","who.int"
"elbasvir + grazoprevir","Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","Oral > Solid: 50 mg + 100 mg","Chronic hepatitis C","","Removed","J05AP54","who.int"
"empagliflozin","Oral hypoglycaemic agents","Oral > Solid: 10 mg; 25 mg","Type 2 diabetes mellitus","","Added","A10BK03","who.int"
"emtricitabine","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Liquid: 10 mg per  mL
Oral > Solid: 200 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AF09","who.int"
"emtricitabine + rilpivirine + tenofovir alafenamide","Fixed-dose combinations of antiretrovirals","Oral > Solid: 200 mg + 25 mg + 25 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AR19","who.int"
"emtricitabine + rilpivirine + tenofovir disoproxil fumarate","Fixed-dose combinations of antiretrovirals","Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AR08","who.int"
"emtricitabine + tenofovir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR03","who.int"
"emtricitabine + tenofovir","Fixed-dose combinations of antiretrovirals","Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)","Contact with or exposure to human immunodeficiency virus","","Added","J05AR03","who.int"
"emtricitabine + tenofovir alafenamide","Fixed-dose combinations of antiretrovirals","Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AR17","who.int"
"enalapril","Antihypertensive medicines","Oral > Liquid: 1 mg per  mL (as hydrogen maleate)
Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)","Essential hypertension","","Added","C09AA02","who.int"
"enalapril","Medicines used in heart failure","Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)","Heart failure","","Added","C09AA02","who.int"
"encorafenib","Targeted therapies","","Other specified melanoma of skin","","Removed","nan","who.int"
"enoxaparin","Medicines affecting coagulation","Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule","Acute ischaemic heart disease","","Added","B01AB05","who.int"
"enoxaparin","Medicines affecting coagulation","Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule","Venous thromboembolism","","Added","B01AB05","who.int"
"entecavir","Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Liquid: 0.05 mg per  mL
Oral > Solid: 0.5 mg; 1 mg","Chronic hepatitis B","","Added","J05AF10","who.int"
"enzalutamide","Hormones and antihormones","
Oral > Solid: 40 mg","Malignant neoplasms of prostate","","Added","nan","who.int"
"enzalutamide","Hormones and antihormones","
Oral > Solid: 40 mg","Malignant neoplasms of prostate","","Removed","L02BB04","who.int"
"ephedrine","Local anaesthetics","Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per  mL in 1 mL ampoule (ephedrine hydrochloride)","Cardiac complications of anaesthesia during labour or delivery","","Added","C01CA26","who.int"
"epinephrine","Antiarrhythmic medicines","Parenteral > General injections > IV: 100 µg per  mL in 10 mL ampoule (as acid tartrate or hydrochloride)","Cardiac arrest","","Added","C01CA24","who.int"
"epinephrine","Ophthalmological preparations > Mydriatics","Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)","Primary open-angle glaucoma","","Added","S01EA01","who.int"
"epinephrine","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Parenteral > General injections > unspecified: 1 mg per  mL in ampoule (as hydrochloride or hydrogen tartrate)","Asthma","","Added","C01CA24","who.int"
"epinephrine","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Parenteral > General injections > unspecified: 1 mg per  mL in ampoule (as hydrochloride or hydrogen tartrate)","Chronic obstructive pulmonary disease","","Added","R03AA01","who.int"
"epinephrine","Antiallergics and medicines used in anaphylaxis","Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)","Anaphylaxis","","Added","C01CA24","who.int"
"epoetin alfa","Antianaemia medicines","","Anaemia due to chronic disease","","Added","nan","who.int"
"epoetin beta","Antianaemia medicines","","Anaemia due to chronic disease","","Added","nan","who.int"
"epoetin theta","Antianaemia medicines","","Anaemia due to chronic disease","","Added","nan","who.int"
"equine rabies immunoglobulin","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > Locoregional injections > Intradermal: 150 IU per  mL in vial; 200 IU per  mL in vial; 300 IU per  mL in vial; 400 IU per  mL in vial","Rabies","","Added","J06BB05","who.int"
"eravacycline","Reserve group antibiotics","Parenteral > General injections > IV: 50 mg lyophilized powder for injection","Carbapenem resistant Enterobacterales","","Removed","J01AA13","who.int"
"ergocalciferol","Vitamins and minerals","
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)","Calcium deficiency","","Added","nan","who.int"
"ergocalciferol","Vitamins and minerals","
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)","Vitamin D deficiency","","Added","nan","who.int"
"ergocalciferol","Vitamins and minerals","
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)","Vitamin D deficiency","","Added","A11CC01","who.int"
"ergocalciferol","Vitamins and minerals","
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)","Calcium deficiency","","Added","A11CC01","who.int"
"ergometrine","Uterotonics","Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)","Postpartum haemorrhage","","Added","G02AB03","who.int"
"erlotinib","Targeted therapies","Oral > Solid: 100 mg; 150 mg","Other specified malignant neoplasms of bronchus or lung","","Added","L01EB02","who.int"
"erythromycin","Watch group antibiotics","Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
Oral > Solid: 250 mg (as stearate or ethylsuccinate)","Bacterial infection of unspecified site","","Removed","J01FA01","who.int"
"erythromycin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 0.5%","Chlamydial conjunctivitis","","Added","S01AA17","who.int"
"erythromycin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 0.5%","Gonococcal infection of eye","","Added","S01AA17","who.int"
"erythropoiesis-stimulating agents","Antianaemia medicines","Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe","Anaemia due to chronic disease","","Added","B03XA03","who.int"
"erythropoiesis-stimulating agents","Antianaemia medicines","Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe","Anaemia due to chronic disease","","Added","B03XA01","who.int"
"erythropoiesis-stimulating agents","Antianaemia medicines","Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe","Anaemia due to chronic disease","","Added","B03XA02","who.int"
"estradiol cypionate + medroxyprogesterone acetate","Injectable hormonal contraceptives","Parenteral > General injections > IM: 5 mg + 25 mg","Contact with health services for reasons associated with reproduction","","Added","G03AA08","who.int"
"etanercept","Immunomodulators for non-malignant disease","","Axial spondyloarthritis","","Added","nan","who.int"
"etanercept","Immunomodulators for non-malignant disease","","Crohn disease site","","Added","nan","who.int"
"etanercept","Immunomodulators for non-malignant disease","","Rheumatoid arthritis","","Added","nan","who.int"
"etanercept","Medicines for juvenile joint diseases","","Juvenile idiopathic arthritis","","Added","nan","who.int"
"ethambutol","Antituberculosis medicines","Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)","Other specified tuberculosis","","Removed","J04AK02","who.int"
"ethambutol","Antituberculosis medicines","Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)","Tuberculosis","","Added","J04AK02","who.int"
"ethambutol + isoniazid","Antituberculosis medicines","Oral > Solid: 400 mg + 150 mg tablet","Tuberculosis","","Removed","J04AM03","who.int"
"ethambutol + isoniazid + pyrazinamide + rifampicin","Antituberculosis medicines","Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet","Tuberculosis","","Added","J04AM06","who.int"
"ethambutol + isoniazid + rifampicin","Antituberculosis medicines","Oral > Solid: 275 mg + 75 mg + 150 mg tablet","Tuberculosis","","Added","J04AK02","who.int"
"ethambutol + isoniazid + rifampicin","Antituberculosis medicines","Oral > Solid: 275 mg + 75 mg + 150 mg tablet","Tuberculosis","","Added","J04AC01","who.int"
"ethambutol + isoniazid + rifampicin","Antituberculosis medicines","Oral > Solid: 275 mg + 75 mg + 150 mg tablet","Tuberculosis","","Added","J04AB02","who.int"
"ethanol","Antiseptics","Local > Topical > Solution: 70% (denatured)","Denatured alcohol","","Added","D08AX08","who.int"
"ether","General anaesthetics and oxygen > Inhalational medicines","Respiratory > Inhalation > solution: ","Anaesthetics and therapeutic gases","","Removed","N01AA01","who.int"
"ethinylestradiol + etonogestrel","Intravaginal contraceptives","Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg","Contact with health services for contraceptive management","","Added","G02BB01","who.int"
"ethinylestradiol + levonorgestrel","Oral hormonal contraceptives","Oral > Solid: 50 µg + 250 µg [4]
Oral > Solid: 30 µg + 150 µg","Contact with health services for postcoital contraception","","Removed","G03AA07","who.int"
"ethinylestradiol + levonorgestrel","Oral hormonal contraceptives","Oral > Solid: 50 µg + 250 µg [4]
Oral > Solid: 30 µg + 150 µg","Contact with health services for contraceptive management","","Added","G03AA07","who.int"
"ethinylestradiol + norethisterone","Oral hormonal contraceptives","Oral > Solid: 35 µg + 1 mg","Contact with health services for contraceptive management","","Added","G03AA05","who.int"
"ethionamide","Antituberculosis medicines","Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04AD03","who.int"
"ethionamide","Antituberculosis medicines","Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)","Tuberculous meningitis","","Added","J04AD03","who.int"
"ethosuximide","Antiseizure medicines","Oral > Liquid: 250 mg per 5 mL
Oral > Solid: 250 mg","Absence seizures, typical","","Added","N03AD01","who.int"
"etonogestrel-releasing implant","Implantable contraceptives","Implant > Subdermal: 68 mg single rod","Contact with health services for insertion of contraceptive device","","Added","G03AC08","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Burkitt lymphoma including Burkitt leukaemia","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Lymphoid leukaemia, not elsewhere classified","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Myeloid leukaemia","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Other specified malignant neoplasms of the ovary","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Other specified malignant neoplasms of bronchus or lung","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Germ cell tumour of testis","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Malignant trophoblastic neoplasms of placenta","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Malignant neoplasms of kidney, except renal pelvis","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Hodgkin lymphoma","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Retinoblastoma","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Anaplastic large cell lymphoma, ALK-negative","","Added","L01CB01","who.int"
"etoposide","Cytotoxic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule","Anaplastic large cell lymphoma, ALK-positive","","Added","L01CB01","who.int"
"everolimus","Targeted therapies","Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)","Other specified gliomas of brain","","Added","L01EG02","who.int"
"fentanyl","Opioid analgesics","Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
Oral > Other: 200 to 1200 µg buccal film (as citrate)","Chronic cancer pain","","Added","N01AH01","who.int"
"fentanyl","Opioid analgesics","Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
Oral > Other: 200 to 1200 µg buccal film (as citrate)","Other specified chronic cancer related pain","","Removed","N02AB03","who.int"
"ferrous salt","Antianaemia medicines","Oral > Liquid: 25 mg per  mL iron (as sulfate)
Oral > Solid: 60 mg iron","Iron deficiency anaemia","","Added","B03AA07","who.int"
"ferrous salt","Antianaemia medicines","Oral > Liquid: 25 mg per  mL iron (as sulfate)
Oral > Solid: 60 mg iron","Iron deficiency anaemia","","Added","B03AA02","who.int"
"ferrous salt + folic acid","Antianaemia medicines","Oral > Solid: 60 mg iron + 2.8 mg","Iron deficiency anaemia","","Removed","B03AD02","who.int"
"ferrous salt + folic acid","Antianaemia medicines","Oral > Solid: 60 mg iron + 2.8 mg","Iron deficiency anaemia","","Removed","B03AD03","who.int"
"ferrous salt + folic acid","Antianaemia medicines","Oral > Solid: 60 mg iron + 2.8 mg","Iron deficiency anaemia","","Removed","B03AD05","who.int"
"fexinidazole","Medicines for the treatment of 1st stage African trypanosomiasis","Oral > Solid: 600 mg","African trypanosomiasis","","Added","P01CA03","who.int"
"fexinidazole","Medicines for the treatment of 2nd stage African trypanosomiasis","Oral > Solid: 600 mg","African trypanosomiasis","","Added","P01CA03","who.int"
"fexofenadine","Antiallergics and medicines used in anaphylaxis","","Allergic or hypersensitivity conditions of unspecified type","","Added","nan","who.int"
"fifth generation cephalosporins","Reserve group antibiotics",".","Other specified bacterial diseases","","Removed","nan","who.int"
"filgrastim","Immunomodulators","Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per  mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial","Acquired neutropaenia","","Added","L03AA02","who.int"
"fingolimod","Immunomodulators for non-malignant disease","Oral > Solid: 0.25 mg; 0.5 mg","Relapsing-remitting multiple sclerosis","","Removed","L04AA27","who.int"
"fluconazole","Antifungal medicines","Parenteral > General injections > IV: 2 mg per  mL in vial
Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
Oral > Solid > capsule: 50 mg","Cryptococcosis","","Added","J02AC01","who.int"
"fluconazole","Antifungal medicines","Parenteral > General injections > IV: 2 mg per  mL in vial
Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
Oral > Solid > capsule: 50 mg","Candidosis","","Added","J02AC01","who.int"
"flucytosine","Antifungal medicines","Parenteral > General injections > IV: 2.5 g per 250 mL infusion
Oral > Solid: 250 mg capsule","Cryptococcosis","","Added","J02AX01","who.int"
"fludarabine","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
Oral > Solid: 10 mg tablet (fludarabine phosphate)","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","L01BB05","who.int"
"fludrocortisone","Adrenal hormones and synthetic substitutes","Oral > Solid: 100 µg (acetate)","Adrenocortical insufficiency","","Added","H02AA02","who.int"
"flunisolide","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"fluorescein","Diagnostic agents > Ophthalmic medicines","Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)","Fluorescein","","Added","S01JA01","who.int"
"fluorouracil","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Ointment: 5%","Plantar warts","","Added","L01BC02","who.int"
"fluorouracil","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01BC02","who.int"
"fluorouracil","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial","Malignant neoplasms of nasopharynx","","Added","L01BC02","who.int"
"fluorouracil","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial","Malignant neoplasm metastasis in large intestine","","Added","L01BC02","who.int"
"fluorouracil","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial","Malignant neoplasms of breast","","Added","L01BC02","who.int"
"fluorouracil","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial","Malignant neoplasms of rectum","","Added","L01BC02","who.int"
"fluorouracil","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial","Malignant neoplasms of colon","","Added","L01BC02","who.int"
"flutamide","Hormones and antihormones","","Malignant neoplasms of prostate","","Added","nan","who.int"
"fluticasone","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"fluticasone + formoterol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"fluticasone furoate + vilanterol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"fluvastatin","Lipid-lowering agents","","Mixed hyperlipidaemia","","Added","nan","who.int"
"fluvastatin","Lipid-lowering agents","","Coronary atherosclerosis","","Added","nan","who.int"
"folic acid","Antianaemia medicines","Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg","Folate deficiency anaemia","","Added","B03BB01","who.int"
"folic acid","Antianaemia medicines","Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg","Anencephaly or similar anomalies","","Added","B03BB01","who.int"
"folic acid","Antianaemia medicines","Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg","Spina bifida","","Added","B03BB01","who.int"
"folic acid","Antianaemia medicines","Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg","Cephalocele","","Added","B03BB01","who.int"
"fomepizole","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 5 mg per  mL in 20 mL ampoule (sulfate); 1 g per  mL in 1.5 mL ampoule (base)","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","V03AB34","who.int"
"fosfomycin (injection)","Reserve group antibiotics","Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","Other specified bacterial diseases","","Removed","J01XX01","who.int"
"fosfomycin (injection)","Reserve group antibiotics","Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","Carbapenem resistant Acinetobacter baumannii","","Added","J01XX01","who.int"
"fosfomycin (injection)","Reserve group antibiotics","Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","Carbapenem-resistant Pseudomonas aeruginosa","","Added","J01XX01","who.int"
"fosfomycin (injection)","Reserve group antibiotics","Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection","Carbapenem resistant Enterobacterales","","Added","J01XX01","who.int"
"fourth generation cephalosporins","Watch group antibiotics",".","Other specified bacterial diseases","","Removed","nan","who.int"
"fresh-frozen plasma","Blood and blood components","Parenteral > General injections > IV: ","Blood transfusion without reported diagnosis","","Added","B05AX03","who.int"
"fulvestrant","Hormones and antihormones","Parenteral > General injections > IV: 250 mg per 5 mL","Malignant neoplasms of breast","","Removed","L02BA03","who.int"
"furosemide","Medicines used in heart failure","Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
Oral > Solid > tablet: 40 mg; 20 mg","Heart failure","","Added","C03CA01","who.int"
"furosemide","Diuretics","Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
Oral > Solid > tablet: 40 mg; 20 mg","Anuria or oliguria","","Added","C03CA01","who.int"
"furosemide","Diuretics","Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
Oral > Solid > tablet: 40 mg; 20 mg","Oedema","","Added","C03CA01","who.int"
"gabapentin","Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg","Neuropathic pain","","Removed","N02BF01","who.int"
"gallamine","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 40 mg per  mL in 2 mL ampoule (gallamine triethiodide)","Muscle relaxants","","Removed","M03AC02","who.int"
"gatifloxacin","Antituberculosis medicines","Oral > Solid: 200 mg; 400 mg","Multi-drug resistant Mycobacterium tuberculosis","","Removed","J01MA16","who.int"
"gefitinib","Targeted therapies","","Other specified malignant neoplasms of bronchus or lung","","Added","nan","who.int"
"gemcitabine","Cytotoxic medicines","Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection","Other specified carcinomas of ovary","","Added","L01BC05","who.int"
"gemcitabine","Cytotoxic medicines","Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection","Other specified malignant neoplasms of bronchus or lung","","Added","L01BC05","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Sepsis without septic shock","amoxicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Sepsis without septic shock","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Sepsis without septic shock","benzylpenicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","benzylpenicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Bacterial pneumonia (Community-acquired pneumonia - severe) [children]","amoxicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Acute malnutrition in infants, children or adolescents (complicated) [children]","benzylpenicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Acute malnutrition in infants, children or adolescents (complicated) [children]","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Peritonitis (mild-moderate)","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Peritonitis (severe)","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Peritoneal abscess (mild-moderate)","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Peritoneal abscess (severe)","ampicillin","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Neonatal meningitis","","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Gonococcal infection","","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Other specified prophylactic measures","","Added","J01GB03","who.int"
"gentamicin","Access group antibiotics","Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)","Bacterial infection of unspecified site","","Removed","J01GB03","who.int"
"gentamicin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)","Other specified conjunctivitis","","Added","S02AA14","who.int"
"gentamicin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)","Infectious blepharitis","","Added","S02AA14","who.int"
"glass ionomer cement","Dental medicines and preparations","Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid","Dental caries","","Added","nan","who.int"
"glatiramer acetate","Medicines for multiple sclerosis","Parenteral > General injections > SC: 20 mg per  mL; 40 mg per  mL
Parenteral > General injections > SC: 20 mg per  mL in pre-filled syringe; 40 mg per  mL in pre-filled syringe","Relapsing-remitting multiple sclerosis","","Removed","L03AX13","who.int"
"glatiramer acetate","Medicines for multiple sclerosis","Parenteral > General injections > SC: 20 mg per  mL; 40 mg per  mL
Parenteral > General injections > SC: 20 mg per  mL in pre-filled syringe; 40 mg per  mL in pre-filled syringe","Multiple sclerosis","","Added","L03AX13","who.int"
"glecaprevir + pibrentasvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules","Chronic hepatitis C","","Added","J05AP57","who.int"
"glibenclamide","Oral hypoglycaemic agents","Oral > Solid: 5 mg; 2.5 mg","Type 2 diabetes mellitus","","Removed","A10BB01","who.int"
"gliclazide","Oral hypoglycaemic agents","Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release","Type 2 diabetes mellitus","","Added","A10BB09","who.int"
"glucagon","Medicines for hypoglycaemia","Parenteral > General injections > unspecified: 1 mg per  mL","Hypoglycaemia in the context of diabetes","","Added","H04AA01","who.int"
"glucose","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
Parenteral > General injections > IV: 50% hypertonic","Other specified disorders of fluid, electrolyte or acid-base balance","","Added","B05CX01","who.int"
"glucose","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
Parenteral > General injections > IV: 50% hypertonic","Hypoglycaemia without associated diabetes","","Added","B05CX01","who.int"
"glucose + sodium chloride","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)","Other specified disorders of fluid, electrolyte or acid-base balance","","Added","nan","who.int"
"glutaral","Disinfectants","Local > Topical > Solution: 2%","Glutaral nonmedicinal","","Added","nan","who.int"
"glyceryl trinitrate","Antianginal medicines","Oral > Solid: 500 µg sublingual tablet","Angina pectoris","","Added","C01DA02","who.int"
"glycopyrronium","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Chronic obstructive pulmonary disease","","Added","nan","who.int"
"golimumab","Immunomodulators for non-malignant disease","","Axial spondyloarthritis","","Added","nan","who.int"
"golimumab","Immunomodulators for non-malignant disease","","Crohn disease site","","Added","nan","who.int"
"golimumab","Immunomodulators for non-malignant disease","","Rheumatoid arthritis","","Added","nan","who.int"
"golimumab","Medicines for juvenile joint diseases","","Juvenile idiopathic arthritis","","Added","nan","who.int"
"goserelin","Hormones and antihormones","","Malignant neoplasms of breast","","Added","nan","who.int"
"goserelin","Hormones and antihormones","","Malignant neoplasms of prostate","","Added","nan","who.int"
"granisetron","Medicines for other common symptoms in palliative care","","Palliative care","","Added","nan","who.int"
"granisetron","Antiemetic medicines","","Nausea or vomiting","","Added","nan","who.int"
"griseofulvin","Antifungal medicines","Oral > Liquid: 125 mg per 5 mL
Oral > Solid: 125 mg; 250 mg","Dermatophytosis","","Added","D01BA01","who.int"
"haemophilus influenzae type b vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AG01","who.int"
"haloperidol","Medicines for other common symptoms in palliative care","Oral > Liquid: 2 mg per  mL
Oral > Solid: 0.5 mg; 2 mg; 5 mg
Parenteral > General injections > unspecified: 5 mg per  mL in 1-mL ampoule","Palliative care","","Added","N05AD01","who.int"
"halothane","General anaesthetics and oxygen > Inhalational medicines","Respiratory > Inhalation > liquid: ","Anaesthetics and therapeutic gases","","Added","N01AB01","who.int"
"heparin sodium","Medicines affecting coagulation","Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule","Acute ischaemic heart disease","","Added","B01AB01","who.int"
"heparin sodium","Medicines affecting coagulation","Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule","Unstable angina","","Added","B01AB01","who.int"
"heparin sodium","Medicines affecting coagulation","Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule","Venous thromboembolism","","Added","B01AB01","who.int"
"hepatitis a vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against viral hepatitis","","Added","J07BC02","who.int"
"hepatitis b vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against viral hepatitis","","Added","J07BC01","who.int"
"homatropine","Ophthalmological preparations > Mydriatics","Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
","Anterior uveitis","","Removed","S01FA05","who.int"
"homatropine","Ophthalmological preparations > Mydriatics","Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
","Anterior uveitis","","Added","nan","who.int"
"human papilloma virus (hpv) vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BM01","who.int"
"hydralazine","Antihypertensive medicines","Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)","Essential hypertension","","Removed","C02DB02","who.int"
"hydralazine","Antihypertensive medicines","Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)","Gestational hypertension","","Added","C02DB02","who.int"
"hydrochlorothiazide","Antihypertensive medicines","Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 25 mg; 12.5 mg","Essential hypertension","","Added","C03AA03","who.int"
"hydrochlorothiazide","Medicines used in heart failure","Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 25 mg","Heart failure","","Added","C03AA03","who.int"
"hydrochlorothiazide","Diuretics","Oral > Solid: 25 mg","Oedema","","Added","C03AA03","who.int"
"hydrocortisone","Hormones and antihormones","Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)","Lymphoid leukaemia, not elsewhere classified","","Added","H02AB09","who.int"
"hydrocortisone","Hormones and antihormones","Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","H02AB09","who.int"
"hydrocortisone","Hormones and antihormones","Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)","Burkitt lymphoma including Burkitt leukaemia","","Added","H02AB09","who.int"
"hydrocortisone","Adrenal hormones and synthetic substitutes","Oral > Solid: 5 mg; 10 mg; 20 mg","Adrenocortical insufficiency","","Added","H02AB09","who.int"
"hydrocortisone","Ophthalmological preparations > Anti-inflammatory agents","Local > Ophthalmological > Ointment: 1% (acetate)","Scleritis","","Removed","S01BA02","who.int"
"hydrocortisone","Ophthalmological preparations > Anti-inflammatory agents","Local > Ophthalmological > Ointment: 1% (acetate)","Anterior uveitis","","Removed","S01BA02","who.int"
"hydrocortisone","Antiallergics and medicines used in anaphylaxis","Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)","Anaphylaxis","","Added","H02AB09","who.int"
"hydrocortisone","Anti-inflammatory medicines","Local > Rectal > Suppository: 25 mg (acetate)
Local > Rectal > Retention enema: 100 mg per 60 mL","Crohn disease site","","Added","A07EA02","who.int"
"hydrocortisone","Anti-inflammatory medicines","Local > Rectal > Suppository: 25 mg (acetate)
Local > Rectal > Retention enema: 100 mg per 60 mL","Ulcerative colitis","","Added","A07EA02","who.int"
"hydrocortisone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)","Dermatitis or eczema","","Added","D07AA02","who.int"
"hydrocortisone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)","Lichen planus","","Added","D07AA02","who.int"
"hydrocortisone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)","Pruritus due to skin disorder","","Added","D07AA02","who.int"
"hydrocortisone","Dermatological medicines > Anti-inflammatory and antipruritic medicines","Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)","Psoriasis of unspecified type","","Added","D07AA02","who.int"
"hydromorphone","Opioid analgesics","","Pain","","Added","nan","who.int"
"hydroxocobalamin","Antianaemia medicines","Parenteral > General injections > IM: 1 mg per  mL in 1 mL ampoule (as acetate); 1 mg per  mL in 1 mL ampoule (as hydrochloride); 1 mg per  mL in 1 mL ampoule (as sulfate)","Megaloblastic anaemia due to vitamin B12 deficiency","","Added","B03BA03","who.int"
"hydroxycarbamide (hydroxyurea)","Cytotoxic medicines","Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg","Squamous cell carcinoma of oropharynx","","Removed","L01XX05","who.int"
"hydroxycarbamide (hydroxyurea)","Cytotoxic medicines","Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg","Chronic myeloid leukaemia, not elsewhere classified","","Added","L01XX05","who.int"
"hydroxycarbamide (hydroxyurea)","Other medicines for haemoglobinopathies","Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg","Other specified sickle cell disorders or other haemoglobinopathies","","Added","L01XX05","who.int"
"hydroxychloroquine","Antimalarial medicines > For chemoprevention","","Malaria due to Plasmodium falciparum","","Removed","nan","who.int"
"hydroxychloroquine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 200 mg (as sulfate)","Systemic lupus erythematosus","","Added","P01BA02","who.int"
"hydroxychloroquine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 200 mg (as sulfate)","Cutaneous lupus erythematosus of unspecified type","","Added","P01BA02","who.int"
"hyoscine butylbromide","Medicines for other common symptoms in palliative care","Parenteral > General injections > unspecified: 20 mg per  mL injection","Palliative care","","Added","A03BB01","who.int"
"hyoscine hydrobromide","Medicines for other common symptoms in palliative care","Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
Parenteral > General injections > unspecified: 400 µg per  mL injection; 600 µg per  mL injection","Palliative care","","Added","A04AD01","who.int"
"hypochlorous acid","Antiseptics","Local > Topical > Solution: ","Disinfectant, not elsewhere classified","","Removed","nan","who.int"
"ibrutinib","Targeted therapies","Oral > Solid: 140 mg","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","L01EL01","who.int"
"ibuprofen","Medicines administered to the neonate [c]","Parenteral > General injections > IV: 5 mg per  mL","Patent arterial duct","","Added","C01EB16","who.int"
"ibuprofen","Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
Oral > Solid > tablet: 200 mg; 400 mg; 600 mg","Pain","","Added","M01AE01","who.int"
"ibuprofen","Antimigraine medicines > For treatment of acute attack","Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
Oral > Solid > tablet: 200 mg; 400 mg","Migraine","","Added","M01AE01","who.int"
"idoxuridine","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 0.1%
Local > Ophthalmological > Ointment: 0.2%","Herpes simplex keratitis","","Removed","S01AD01","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Other specified malignant neoplasms of the ovary","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Germ cell tumour of testis","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Rhabdomyosarcoma primary site","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Burkitt lymphoma including Burkitt leukaemia","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Malignant neoplasms of kidney, except renal pelvis","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Anaplastic large cell lymphoma, ALK-negative","","Added","L01AA06","who.int"
"ifosfamide","Cytotoxic medicines","Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection","Anaplastic large cell lymphoma, ALK-positive","","Added","L01AA06","who.int"
"imatinib","Targeted therapies","Oral > Solid: 100 mg; 400 mg","B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1","","Added","L01EA01","who.int"
"imatinib","Targeted therapies","Oral > Solid: 100 mg; 400 mg","Gastrointestinal stromal tumour of unspecified gastrointestinal sites","","Added","L01EA01","who.int"
"imatinib","Targeted therapies","Oral > Solid: 100 mg; 400 mg","Chronic myeloid leukaemia, not elsewhere classified","","Added","L01EA01","who.int"
"imipenem + cilastatin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
","Peritonitis (severe)","","Added","J01DH02","who.int"
"imipenem + cilastatin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
","Peritoneal abscess (severe)","","Added","J01DH02","who.int"
"imipenem + cilastatin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
","Neutropenia (high-risk)","","Added","J01DH02","who.int"
"imipenem + cilastatin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
","Pseudomonas aeruginosa resistant to other antibiotic","","Removed","J01DH51","who.int"
"imipenem + cilastatin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
","Antibiotic resistant Acinetobacter baumannii","","Removed","J01DH51","who.int"
"imipenem + cilastatin","Antituberculosis medicines","","Multi-drug resistant Mycobacterium tuberculosis","","Added","nan","who.int"
"imipenem + cilastatin + relebactam","Reserve group antibiotics","Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection","Other specified other antibiotic resistant Enterobacterales","","Removed","J01DH56","who.int"
"imipenem + cilastatin + relebactam","Reserve group antibiotics","Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection","Carbapenem resistant Enterobacterales","","Removed","J01DH56","who.int"
"imipenem + cilastatin + relebactam","Reserve group antibiotics","Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection","Carbapenem-resistant Pseudomonas aeruginosa","","Removed","J01DH56","who.int"
"indapamide","Antihypertensive medicines","","Essential hypertension","","Added","nan","who.int"
"indapamide","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"indinavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 400 mg (as sulfate)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AE02","who.int"
"indometacin","Medicines administered to the neonate [c]","","Patent arterial duct","","Added","nan","who.int"
"infliximab","Immunomodulators for non-malignant disease","","Axial spondyloarthritis","","Added","nan","who.int"
"infliximab","Immunomodulators for non-malignant disease","","Crohn disease site","","Added","nan","who.int"
"infliximab","Immunomodulators for non-malignant disease","","Rheumatoid arthritis","","Added","nan","who.int"
"infliximab","Medicines for juvenile joint diseases","","Juvenile idiopathic arthritis","","Added","nan","who.int"
"influenza vaccine (seasonal)","Recommendations for immunization programmes with certain characteristics","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against influenza","","Added","J07BB01","who.int"
"influenza vaccine (seasonal)","Recommendations for immunization programmes with certain characteristics","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against influenza","","Added","J07BB02","who.int"
"influenza vaccine (seasonal)","Recommendations for immunization programmes with certain characteristics","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against influenza","","Added","J07BB03","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AE04","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AE05","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AB05","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AD05","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AB04","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AC04","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AD04","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AB06","who.int"
"insulin analogues","Insulins","Not specified","Type 1 diabetes mellitus","","Removed","A10AE06","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AE04","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AE05","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AB05","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AD05","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AB04","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AC04","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AD04","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AB06","who.int"
"insulin analogues","Insulins","Not specified","Type 2 diabetes mellitus","","Removed","A10AE06","who.int"
"insulin degludec","Insulins","Parenteral > General injections > SC: 100 units per  mL
","Type 1 diabetes mellitus","","Removed","nan","who.int"
"insulin degludec","Insulins","Parenteral > General injections > SC: 100 units per  mL
","Type 1 diabetes mellitus","","Added","nan","who.int"
"insulin degludec","Insulins","Parenteral > General injections > SC: 100 units per  mL
","Type 2 diabetes mellitus","","Added","nan","who.int"
"insulin detemir","Insulins","","Type 1 diabetes mellitus","","Removed","nan","who.int"
"insulin detemir","Insulins","","Type 1 diabetes mellitus","","Added","nan","who.int"
"insulin detemir","Insulins","","Type 2 diabetes mellitus","","Added","nan","who.int"
"insulin glargine","Insulins","Parenteral > General injections > SC: 100 units per  mL
","Type 1 diabetes mellitus","","Removed","A10AE04","who.int"
"insulin glargine","Insulins","Parenteral > General injections > SC: 100 units per  mL
","Type 1 diabetes mellitus","","Added","nan","who.int"
"insulin glargine","Insulins","Parenteral > General injections > SC: 100 units per  mL
","Type 2 diabetes mellitus","","Added","nan","who.int"
"intraperitoneal dialysis solution","Peritoneal dialysis solution","parenteral solution","Care involving peritoneal dialysis","","Added","nan","who.int"
"iodine","Vitamins and minerals","Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
Oral > Solid: 190 mg","Iodine deficiency","","Added","H03CA","who.int"
"iodine","Antiseptics","","Povidone iodine","","Added","nan","who.int"
"iohexol","Diagnostic agents > Radiocontrast media","Parenteral > General injections > unspecified: 140 to 350 mg iodine per  mL in 5 mL ampoule; 140 to 350 mg iodine per  mL in 10 mL ampoule; 140 to 350 mg iodine per  mL in 20 mL ampoule","X-ray contrast media, iodinated","","Added","V08AB02","who.int"
"ipecacuanha","Antidotes and other substances used in poisonings > Non-specific","Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine","Unspecified injury, poisoning or certain other consequences of external causes","","Removed","V03AB01","who.int"
"ipratropium bromide","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Respiratory > Inhalation > aerosol: 20 µg per  dose","Asthma","","Added","R03BB01","who.int"
"ipratropium bromide","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Respiratory > Inhalation > aerosol: 20 µg per  dose","Chronic obstructive pulmonary disease","","Added","R03BB01","who.int"
"irinotecan","Cytotoxic medicines","Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial","Malignant neoplasm metastasis in large intestine","","Added","L01CE02","who.int"
"irinotecan","Cytotoxic medicines","Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial","Malignant neoplasms of kidney, except renal pelvis","","Added","L01CE02","who.int"
"irinotecan","Cytotoxic medicines","Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial","Rhabdomyosarcoma primary site","","Added","L01CE02","who.int"
"isoflurane","General anaesthetics and oxygen > Inhalational medicines","Respiratory > Inhalation > liquid: ","Anaesthetics and therapeutic gases","","Added","N01AB06","who.int"
"isoniazid","Antituberculosis medicines","Parenteral > General injections > IV: 100 mg per  mL
Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet","Other specified tuberculosis","","Removed","J04AC01","who.int"
"isoniazid","Antituberculosis medicines","Parenteral > General injections > IV: 100 mg per  mL
Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet","Tuberculosis","","Added","J04AC01","who.int"
"isoniazid + pyrazinamide + rifampicin","Antituberculosis medicines","Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)","Tuberculosis","","Added","J04AM05","who.int"
"isoniazid + pyridoxine + sulfamethoxazole + trimethoprim","Medicines for prevention of HIV-related opportunistic infections","Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)","Other specified prophylactic measures","","Added","J04AC51","who.int"
"isoniazid + rifampicin","Antituberculosis medicines","Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet","Tuberculosis","","Added","J04AM02","who.int"
"isoniazid + rifapentine","Antituberculosis medicines","Oral > Solid: 300 mg + 300 mg tablet (scored)","Latent tuberculosis","","Added","J04AC51","who.int"
"isoprenaline","Antiarrhythmic medicines","Parenteral > General injections > IV: 20 µg per  mL in ampoule (hydrochloride)
Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)","Bradycardia","","Removed","C01CA02","who.int"
"isoprenaline","Antiarrhythmic medicines","Parenteral > General injections > IV: 20 µg per  mL in ampoule (hydrochloride)
Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)","Cardiogenic shock","","Removed","C01CA02","who.int"
"isosorbide dinitrate","Antianginal medicines","Oral > Solid: 5 mg sublingual tablet","Angina pectoris","","Added","C01DA08","who.int"
"itraconazole","Antifungal medicines","Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg","Chronic pulmonary aspergillosis","","Added","J02AC02","who.int"
"itraconazole","Antifungal medicines","Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg","Chromoblastomycosis","","Added","J02AC02","who.int"
"itraconazole","Antifungal medicines","Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg","Histoplasmosis","","Added","J02AC02","who.int"
"itraconazole","Antifungal medicines","Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg","Talaromycosis","","Added","J02AC02","who.int"
"itraconazole","Antifungal medicines","Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg","Sporotrichosis","","Added","J02AC02","who.int"
"itraconazole","Antifungal medicines","Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg","Paracoccidioidomycosis","","Added","J02AC02","who.int"
"ivermectin","Intestinal anthelminthics","Oral > Solid > tablet: 3 mg","Strongyloidiasis","","Added","P02CF01","who.int"
"ivermectin","Intestinal anthelminthics","Oral > Solid > tablet: 3 mg","Ascariasis","","Added","P02CF01","who.int"
"ivermectin","Intestinal anthelminthics","Oral > Solid > tablet: 3 mg","Trichuriasis","","Added","P02CF01","who.int"
"ivermectin","Intestinal anthelminthics","Oral > Solid > tablet: 3 mg","Hookworm diseases","","Added","P02CF01","who.int"
"ivermectin","Intestinal anthelminthics","Oral > Solid > tablet: 3 mg","Ancylostomiasis","","Added","P02CF01","who.int"
"ivermectin","Antifilarials","Oral > Solid > tablet: 3 mg","Onchocerciasis","","Added","P02CF01","who.int"
"ivermectin","Antifilarials","Oral > Solid > tablet: 3 mg","Lymphatic filariasis","","Added","P02CF01","who.int"
"ivermectin","Medicines for ectoparasitic infections","Oral > Solid > tablet: 3 mg","Scabies","","Added","P02CF01","who.int"
"kanamycin","Ophthalmological preparations > Anti-infective agents","","Other specified conjunctivitis","","Added","nan","who.int"
"kanamycin","Ophthalmological preparations > Anti-infective agents","","Infectious blepharitis","","Added","nan","who.int"
"kanamycin (injection)","Antituberculosis medicines","Parenteral > General injections > IV: 1000 mg powder for injection (vial)","Multi-drug resistant Mycobacterium tuberculosis","","Removed","J01GB04","who.int"
"ketamine","General anaesthetics and oxygen > Injectable medicines","Parenteral > General injections > unspecified: 50 mg per  mL in 10 mL vial (as hydrochloride)","Anaesthetics and therapeutic gases","","Added","N01AX03","who.int"
"lactulose","Medicines for other common symptoms in palliative care","Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid","Palliative care","","Added","A06AD11","who.int"
"lamivudine","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 150 mg tablet","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AF05","who.int"
"lamivudine + nevirapine + zidovudine","Fixed-dose combinations of antiretrovirals","Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AR05","who.int"
"lamivudine + tenofovir","Fixed-dose combinations of antiretrovirals","","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","nan","who.int"
"lamivudine + tenofovir","Fixed-dose combinations of antiretrovirals","","Contact with or exposure to human immunodeficiency virus","","Added","nan","who.int"
"lamivudine + zidovudine","Fixed-dose combinations of antiretrovirals","Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR01","who.int"
"lamotrigine","Antiseizure medicines","Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)","Epilepsy or seizures","","Added","N03AX09","who.int"
"latanoprost","Ophthalmological preparations > Miotics and antiglaucoma medicines","Local > Ophthalmological > Solution (eye drops): 50 µg per  mL eye drops","Primary open-angle glaucoma","","Added","S01EE01","who.int"
"ledipasvir + sofosbuvir","Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","Oral > Solid: 90 mg + 400 mg tablet","Chronic hepatitis C","","Added","J05AP51","who.int"
"lenalidomide","Immunomodulators","Oral > Solid: 25 mg","Plasma cell myeloma","","Added","L04AX04","who.int"
"leuprorelin","Hormones and antihormones","Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe","Malignant neoplasms of breast","","Added","L02AE02","who.int"
"leuprorelin","Hormones and antihormones","Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe","Malignant neoplasms of prostate","","Added","L02AE02","who.int"
"levamisole","Intestinal anthelminthics","Oral > Solid > tablet: 50 mg  (as hydrochloride); 150 mg  (as hydrochloride)","Ascariasis","","Added","P02CE01","who.int"
"levetiracetam","Antiseizure medicines","Oral > Liquid: 100 mg per  mL
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per  mL in 100 mL bag; 10 mg per  mL in 100 mL bag; 15 mg per  mL in 100 mL bag","Epilepsy or seizures","","Added","N03AX14","who.int"
"levetiracetam","Antiseizure medicines","Oral > Liquid: 100 mg per  mL
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per  mL in 100 mL bag; 10 mg per  mL in 100 mL bag; 15 mg per  mL in 100 mL bag","Status epilepticus","","Added","N03AX14","who.int"
"levodopa","Antiseizure medicines","Oral > Solid: 250 mg","Parkinson disease","","Removed","N04BA01","who.int"
"levodopa + benserazide","Medicines for parkinsonism","","Parkinson disease","","Added","nan","who.int"
"levodopa + carbidopa","Medicines for parkinsonism","Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet","Parkinson disease","","Added","N04BA02","who.int"
"levofloxacin","Antituberculosis medicines","Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01MA12","who.int"
"levonorgestrel","Oral hormonal contraceptives","Oral > Solid: 750 µg [2]; 1.5 mg [1]
Oral > Solid: 30 µg","Contact with health services for postcoital contraception","","Added","G03AD01","who.int"
"levonorgestrel","Oral hormonal contraceptives","Oral > Solid: 750 µg [2]; 1.5 mg [1]
Oral > Solid: 30 µg","Contact with health services for contraceptive management","","Added","G03AC03","who.int"
"levonorgestrel","Intrauterine devices","Intrauterine system with reservoir containing 52 mg of levonorgestrel.","Contact with health services for insertion of contraceptive device","","Added","G02BA03","who.int"
"levonorgestrel-releasing implant","Implantable contraceptives","Implant > Subdermal: 75 mg per  rod (two-rods)","Contact with health services for insertion of contraceptive device","","Added","G03AC03","who.int"
"levothyroxine","Thyroid hormones and antithyroid medicines","Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)","Hypothyroidism","","Added","H03AA01","who.int"
"lidocaine","Antiarrhythmic medicines","Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule (hydrochloride)","Ventricular tachyarrhythmia","","Added","C01BB01","who.int"
"lidocaine","Local anaesthetics","Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
Local > Topical > unspecified: 2 to 4% (hydrochloride)","Local anaesthetics","","Added","N01BB02","who.int"
"lidocaine + epinephrine","Local anaesthetics","Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine","Local anaesthetics","","Added","N01BB52","who.int"
"lindane","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Cream: 1%
Local > Topical > Lotion: 1%","Scabies","","Removed","P03AB02","who.int"
"linezolid","Reserve group antibiotics","Parenteral > General injections > IV: 2 mg per  mL in 300 mL bag
Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid: 400 mg tablet; 600 mg tablet","Other specified bacterial diseases","","Removed","J01XX08","who.int"
"linezolid","Antituberculosis medicines","Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01XX08","who.int"
"lisinopril + amlodipine","Antihypertensive medicines","Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg","Essential hypertension","","Added","C09BB03","who.int"
"lisinopril + hydrochlorothiazide","Antihypertensive medicines","Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg","Essential hypertension","","Added","C09BA03","who.int"
"lisocabtagene maraleucel","Antineoplastics and supportive medicines","","Diffuse large B-cell lymphomas","","Removed","nan","who.int"
"lithium carbonate","Medicines for bipolar disorders","Oral > Solid: 300 mg","Bipolar or related disorders","","Added","N05AN01","who.int"
"long-acting insulin analogues","Insulins","Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","Type 1 diabetes mellitus","","Added","A10AE06","who.int"
"long-acting insulin analogues","Insulins","Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","Type 1 diabetes mellitus","","Added","A10AE05","who.int"
"long-acting insulin analogues","Insulins","Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","Type 1 diabetes mellitus","","Added","A10AE04","who.int"
"long-acting insulin analogues","Insulins","Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","Type 2 diabetes mellitus","","Added","A10AE06","who.int"
"long-acting insulin analogues","Insulins","Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","Type 2 diabetes mellitus","","Added","A10AE05","who.int"
"long-acting insulin analogues","Insulins","Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen","Type 2 diabetes mellitus","","Added","A10AE04","who.int"
"loperamide","Medicines for other common symptoms in palliative care","Oral > Solid: 2 mg solid oral dosage form","Palliative care","","Added","A07DA03","who.int"
"lopinavir + ritonavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AR10","who.int"
"loratadine","Antiallergics and medicines used in anaphylaxis","Oral > Liquid: 1 mg per  mL
Oral > Solid: 10 mg","Allergic or hypersensitivity conditions of unspecified type","","Added","R06AX13","who.int"
"lorazepam","Antiseizure medicines","Parenteral > General injections > IV: 2 mg per  mL in 1 mL ampoule; 4 mg per  mL in 1 mL ampoule","Status epilepticus","","Added","N05BA06","who.int"
"losartan","Antihypertensive medicines","Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet","Essential hypertension","","Added","C09CA01","who.int"
"losartan","Medicines used in heart failure","Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet","Heart failure","","Added","C09CA01","who.int"
"lovastatin","Lipid-lowering agents","","Mixed hyperlipidaemia","","Added","nan","who.int"
"lovastatin","Lipid-lowering agents","","Coronary atherosclerosis","","Added","nan","who.int"
"lugol's solution","Thyroid hormones and antithyroid medicines","Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)","Thyrotoxicosis","","Added","H03CA","who.int"
"magnesium sulfate","Antiseizure medicines","Parenteral > General injections > IV: 500 mg per  mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
Parenteral > General injections > IM: 500 mg per  mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)","Severe pre-eclampsia","","Added","B05XA05","who.int"
"magnesium sulfate","Antiseizure medicines","Parenteral > General injections > IV: 500 mg per  mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
Parenteral > General injections > IM: 500 mg per  mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)","Eclampsia","","Added","B05XA05","who.int"
"mannitol","Diuretics","Parenteral > General injections > IV: 10% solution; 20% solution","Ocular hypertension","","Added","B05BC01","who.int"
"mannitol","Diuretics","Parenteral > General injections > IV: 10% solution; 20% solution","Cerebral oedema","","Added","B05BC01","who.int"
"measles vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against measles alone","","Added","J07BD01","who.int"
"mebendazole","Intestinal anthelminthics","Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","Ascariasis","","Added","P02CA01","who.int"
"mebendazole","Intestinal anthelminthics","Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","Enterobiasis","","Added","P02CA01","who.int"
"mebendazole","Intestinal anthelminthics","Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","Trichuriasis","","Added","P02CA01","who.int"
"mebendazole","Intestinal anthelminthics","Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)","Hookworm diseases","","Added","P02CA01","who.int"
"mebendazole","Cysticidal medicines","Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)","Other specified echinococcosis","","Added","P02CA01","who.int"
"medroxyprogesterone acetate","Injectable hormonal contraceptives","Parenteral > General injections > IM: 150 mg per  mL in 1 mL vial
Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system","Contact with health services for reasons associated with reproduction","","Added","G03AC06","who.int"
"medroxyprogesterone acetate","Progestogens","Oral > Solid: 5 mg","Excessive menstruation with irregular cycle","","Added","G03DA02","who.int"
"mefloquine","Antimalarial medicines > For curative treatment","Oral > Solid: 250 mg tablet (hydrochloride)","Malaria due to Plasmodium falciparum","","Added","P01BC02","who.int"
"mefloquine","Antimalarial medicines > For curative treatment","Oral > Solid: 250 mg tablet (hydrochloride)","Malaria due to Plasmodium vivax","","Added","P01BC02","who.int"
"mefloquine","Antimalarial medicines > For chemoprevention","Oral > Solid: 250 mg tablet (hydrochloride)","Malaria due to Plasmodium falciparum","","Added","P01BC02","who.int"
"meglumine antimoniate","Antileishmaniasis medicines","Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule","Visceral leishmaniasis","","Added","P01CB01","who.int"
"meglumine antimoniate","Antileishmaniasis medicines","Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule","Mucocutaneous leishmaniasis","","Added","P01CB01","who.int"
"meglumine antimoniate","Antileishmaniasis medicines","Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule","Cutaneous leishmaniasis","","Added","P01CB01","who.int"
"meglumine iotroxate","Diagnostic agents > Radiocontrast media","Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL","X-ray contrast media, iodinated","","Added","V08AC02","who.int"
"melarsoprol","Medicines for the treatment of 2nd stage African trypanosomiasis","Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)","African trypanosomiasis","","Added","P01CD01","who.int"
"melphalan","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection
Oral > Solid: 2 mg","Plasma cell myeloma","","Added","L01AA03","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH01","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH02","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH03","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH04","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH05","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH06","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH07","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH08","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH09","who.int"
"meningococcal meningitis vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AH10","who.int"
"mercaptopurine","Cytotoxic medicines","Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01BB02","who.int"
"mercaptopurine","Cytotoxic medicines","Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","L01BB02","who.int"
"mercaptopurine","Cytotoxic medicines","Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL","Lymphoid leukaemia, not elsewhere classified","","Added","L01BB02","who.int"
"mercaptopurine","Cytotoxic medicines","Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL","Langerhans cell histiocytosis","","Added","L01BB02","who.int"
"meropenem","Watch group antibiotics","Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","Neonatal meningitis","","Added","J01DH02","who.int"
"meropenem","Watch group antibiotics","Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","Peritonitis (severe)","","Added","J01DH02","who.int"
"meropenem","Watch group antibiotics","Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","Peritoneal abscess (severe)","","Added","J01DH02","who.int"
"meropenem","Watch group antibiotics","Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","Neutropenia (high-risk)","","Added","J01DH02","who.int"
"meropenem","Antituberculosis medicines","Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01DH02","who.int"
"meropenem + vaborbactam","Reserve group antibiotics","Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection","Carbapenem-resistant Pseudomonas aeruginosa","","Added","J01DH52","who.int"
"meropenem + vaborbactam","Reserve group antibiotics","Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection","Carbapenem resistant Enterobacterales","","Added","J01DH52","who.int"
"meropenem + vaborbactam","Reserve group antibiotics","Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection","Carbapenem resistant Acinetobacter baumannii","","Added","J01DH52","who.int"
"mesalazine","Anti-inflammatory medicines","","Crohn disease site","","Added","nan","who.int"
"mesalazine","Anti-inflammatory medicines","","Ulcerative colitis","","Added","nan","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Osteosarcoma of bone and articular cartilage of other specified sites","","Added","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Other specified malignant neoplasms of the ovary","","Added","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Germ cell tumour of testis","","Added","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Rhabdomyosarcoma primary site","","Added","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Burkitt lymphoma including Burkitt leukaemia","","Added","V03AF01","who.int"
"mesna","Supportive medicines","Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg","Malignant neoplasms of kidney, except renal pelvis","","Added","V03AF01","who.int"
"metformin","Oral hypoglycaemic agents","Oral > Solid: 500 mg (hydrochloride)","Type 2 diabetes mellitus","","Added","A10BA02","who.int"
"methadone","Medicines for opioid use disorders","Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per  mL concentrate for oral liquid (methadone hydrochloride); 10 mg per  mL concentrate for oral liquid (methadone hydrochloride)","Opioid dependence","","Added","N07BC02","who.int"
"methadone","Opioid analgesics","Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per  mL concentrate for oral liquid (methadone hydrochloride); 10 mg per  mL concentrate for oral liquid (methadone hydrochloride)
Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)","Chronic cancer pain","","Added","N07BC02","who.int"
"methimazole","Thyroid hormones and antithyroid medicines","Oral > Solid: 5 mg; 10 mg; 20 mg","Thyrotoxicosis","","Added","H03BB02","who.int"
"methionine","Antidotes and other substances used in poisonings > Specific","Oral > Solid: 250 mg (DL)","Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs","","Removed","V03AB26","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Lymphoid leukaemia, not elsewhere classified","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Malignant trophoblastic neoplasms of placenta","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Burkitt lymphoma including Burkitt leukaemia","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Malignant neoplasms of breast","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Osteosarcoma of bone and articular cartilage of unspecified sites","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Anaplastic large cell lymphoma, ALK-negative","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Anaplastic large cell lymphoma, ALK-positive","","Added","L01BA01","who.int"
"methotrexate","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection","Langerhans cell histiocytosis","","Added","L01BA01","who.int"
"methotrexate","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)","Psoriasis of unspecified type","","Added","L04AX03","who.int"
"methotrexate","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid > tablet: 2.5 mg (as sodium salt)","Rheumatoid arthritis, serology unspecified","","Added","L04AX03","who.int"
"methotrexate","Immunomodulators for non-malignant disease","Parenteral > General injections > SC: pre-filled syringe in multiple strengths","Crohn disease site","","Removed","L04AX03","who.int"
"methotrexate","Immunomodulators for non-malignant disease","Parenteral > General injections > SC: pre-filled syringe in multiple strengths","Psoriatic arthritis","","Removed","L04AX03","who.int"
"methotrexate","Medicines for juvenile joint diseases","Oral > Solid > tablet: 2.5 mg (as sodium salt)","Juvenile idiopathic arthritis","","Added","L04AX03","who.int"
"methoxy polyethylene glycol-epoetin beta","Antianaemia medicines","","Anaemia due to chronic disease","","Added","nan","who.int"
"methyldopa","Antihypertensive medicines","Oral > Solid: 250 mg","Essential hypertension","","Removed","C02AB01","who.int"
"methyldopa","Antihypertensive medicines","Oral > Solid: 250 mg","Gestational hypertension","","Added","C02AB01","who.int"
"methylergometrine","Uterotonics","","Postpartum haemorrhage","","Added","nan","who.int"
"methylphenidate","Medicines for mental and behavioural disorders","Multiple formulations and strengths.","Attention deficit hyperactivity disorder","","Removed","N06BA04","who.int"
"methylprednisolone","Hormones and antihormones","Parenteral > General injections > IV: 40 mg per  mL in 1 mL single-dose vial (as sodium succinate); 40 mg per  mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per  mL in 1 mL single-dose vial (as sodium succinate)","Lymphoid leukaemia, not elsewhere classified","","Added","H02AB04","who.int"
"methylprednisolone","Hormones and antihormones","Parenteral > General injections > IV: 40 mg per  mL in 1 mL single-dose vial (as sodium succinate); 40 mg per  mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per  mL in 1 mL single-dose vial (as sodium succinate)","Burkitt lymphoma including Burkitt leukaemia","","Added","H02AB04","who.int"
"methylthioninium chloride","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 10 mg per  mL in 10 mL ampoule","Acquired methaemoglobinaemia","","Added","V03AB17","who.int"
"metoclopramide","Medicines for other common symptoms in palliative care","Oral > Liquid: 5 mg per 5 mL
Oral > Solid: 10 mg (hydrochloride)
Parenteral > General injections > unspecified: 5 mg per  mL in 2 mL ampoule (hydrochloride)","Palliative care","","Added","A03FA01","who.int"
"metoclopramide","Antiemetic medicines","Oral > Liquid: 5 mg per 5 mL
Oral > Solid: 10 mg (hydrochloride)
Parenteral > General injections > unspecified: 5 mg per  mL in 2 mL ampoule (hydrochloride)","Nausea or vomiting","","Added","A03FA01","who.int"
"metoprolol","Antianginal medicines","","Angina pectoris","","Added","nan","who.int"
"metoprolol","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"metoprolol","Antihypertensive medicines","","Essential hypertension","","Added","nan","who.int"
"metoprolol","Antiarrhythmic medicines","","Cardiac arrhythmia","","Added","nan","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritonitis (mild-moderate)","cefotaxime","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritonitis (severe)","cefotaxime","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritonitis (mild-moderate)","ceftriaxone","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritonitis (severe)","ceftriaxone","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritoneal abscess (mild-moderate)","cefotaxime","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritoneal abscess (severe)","cefotaxime","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritoneal abscess (mild-moderate)","ceftriaxone","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritoneal abscess (severe)","ceftriaxone","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Other specified prophylactic measures","cefazolin","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritonitis (mild-moderate)","ciprofloxacin","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Peritoneal abscess (mild-moderate)","ciprofloxacin","Added","A01AB17","who.int"
"metronidazole","Access group antibiotics","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository","Bacterial infection of unspecified site","","Removed","A01AB17","who.int"
"metronidazole","Antiamoebic and antigiardiasis medicines","Oral > Liquid: 200 mg per 5 mL (as benzoate)
Parenteral > General injections > unspecified: 500 mg in 100 mL vial
Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg","Amoebiasis","","Added","P01AB01","who.int"
"micafungin","Antifungal medicines","Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection","Systemic or invasive candidosis","","Added","J02AX05","who.int"
"miconazole","Dermatological medicines > Antifungal medicines","Local > Topical > Cream: 2% (nitrate)
Local > Topical > Ointment: 2% (nitrate)","Fungal infection of the skin","","Added","D01AC02","who.int"
"midazolam","Medicines for other common symptoms in palliative care","Oral > Liquid: 2 mg per  mL oral liquid
Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
Parenteral > General injections > unspecified: 1 mg per  mL injection; 5 mg per  mL injection","Palliative care","","Added","N05CD08","who.int"
"midazolam","Antiseizure medicines","
Parenteral > General injections > unspecified: 1 mg per  mL in 5 mL vial (for buccal administration); 5 mg per  mL in 1 mL vial (for buccal administration); 5 mg per  mL in 3 mL vial (for buccal administration)
Local > Buccal > Solution: 5 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.75 mL pre-filled syringe; 10 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration)","Status epilepticus","","Added","nan","who.int"
"midazolam","Antiseizure medicines","
Parenteral > General injections > unspecified: 1 mg per  mL in 5 mL vial (for buccal administration); 5 mg per  mL in 1 mL vial (for buccal administration); 5 mg per  mL in 3 mL vial (for buccal administration)
Local > Buccal > Solution: 5 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.75 mL pre-filled syringe; 10 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration)","Status epilepticus","","Added","N05CD08","who.int"
"midazolam","Preoperative medication and sedation for short-term procedures","Parenteral > General injections > IV: 1 mg per  mL
Oral > Liquid: 2 mg per  mL
Oral > Solid: 15 mg  tablet; 7.5 mg tablet","Sedative-hypnotic and anxiolytic drugs","","Added","N05CD08","who.int"
"mifepristone - misoprostol","Uterotonics","Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package","Induced abortion","","Added","G03XB51","who.int"
"miltefosine","Antileishmaniasis medicines","Oral > Solid: 10 mg; 50 mg","Visceral leishmaniasis","","Added","P01CX04","who.int"
"miltefosine","Antileishmaniasis medicines","Oral > Solid: 10 mg; 50 mg","Mucocutaneous leishmaniasis","","Added","P01CX04","who.int"
"miltefosine","Antileishmaniasis medicines","Oral > Solid: 10 mg; 50 mg","Cutaneous leishmaniasis","","Added","P01CX04","who.int"
"misoprostol","Uterotonics","Oral > Solid: 200 µg
Local > Vaginal > tablet: 25 µg","Spontaneous abortion, incomplete, without complication","","Added","G02AD06","who.int"
"misoprostol","Uterotonics","Oral > Solid: 200 µg
Local > Vaginal > tablet: 25 µg","Unspecified obstetric condition","","Added","G02AD06","who.int"
"misoprostol","Uterotonics","Oral > Solid: 200 µg
Local > Vaginal > tablet: 25 µg","Postpartum haemorrhage","","Added","G02AD06","who.int"
"mometasone","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"mometasone + formoterol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"morphine","Preoperative medication and sedation for short-term procedures","Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)","Opioids or related analgesics and agents affecting opioid receptors","","Added","N02AA01","who.int"
"morphine","Opioid analgesics","Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)","Pain","","Added","N02AA01","who.int"
"moxifloxacin","Antituberculosis medicines","Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
Oral > Solid: 400 mg tablet","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01MA14","who.int"
"moxifloxacin","Antituberculosis medicines","Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
Oral > Solid: 400 mg tablet","Tuberculosis","","Added","J01MA14","who.int"
"multiple micronutrient powder","Vitamins and minerals","Oral > Other: ","Iron deficiency anaemia","","Added","A11AA01","who.int"
"multiple micronutrient supplement","Other medicines administered to the mother","Tablet containing: 
Vit A: 800 mcg retinol activity equivalent
Vit C: 70 mg
Vit D: 5 mcg (200 IU)
Vit E: 10 mg alpha tocopherol equivalent
Vit B1: 1.4 mg
Vit B2: 1.4 mg
Vit B3: 18 mg niacin equivalent
Vit B6: 1.9 mg
Folic acid: 400 mcg
Vit B12: 2.6 mcg
Iron: 30 mg
Iodine: 150 mcg
Zinc: 15 mg
Selenium: 65 mcg
Copper: 2 mg","Maternal care for other specified conditions predominantly related to pregnancy","","Added","A11AA01","who.int"
"mumps vaccine","Recommendations for immunization programmes with certain characteristics","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against mumps alone","","Added","J07BE01","who.int"
"mupirocin","Dermatological medicines > Anti-infective medicines","Local > Topical > Cream: 2% (as mupirocin calcium)
Local > Topical > Ointment: 2%","Superficial bacterial folliculitis","","Added","D06AX09","who.int"
"mupirocin","Dermatological medicines > Anti-infective medicines","Local > Topical > Cream: 2% (as mupirocin calcium)
Local > Topical > Ointment: 2%","Impetigo","","Added","D06AX09","who.int"
"nadroparin","Medicines affecting coagulation","","Acute ischaemic heart disease","","Added","nan","who.int"
"nadroparin","Medicines affecting coagulation","","Venous thromboembolism","","Added","nan","who.int"
"nalidixic acid","Anti-infective medicines","Oral > Solid: 250 mg; 500 mg","Shigella resistant to unspecified antibiotic","","Removed","J01MB02","who.int"
"naloxone","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)","Unintentional exposure to or harmful effects of opioids or related analgesics","","Added","V03AB15","who.int"
"natamycin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Suspension: 5% eye drops","Infectious keratitis","","Added","S01AA10","who.int"
"nelfinavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 250 mg (as mesilate)
Oral > Other: 50 mg per  g oral powder","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AE04","who.int"
"neostigmine","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Oral > Solid: 15 mg (neostigmine bromide)
Parenteral > General injections > unspecified: 0.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate)","Myasthenia gravis","","Added","N07AA01","who.int"
"neostigmine","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Oral > Solid: 15 mg (neostigmine bromide)
Parenteral > General injections > unspecified: 0.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate)","Anticholinesterase reversible","","Added","N07AA01","who.int"
"netilmicin","Ophthalmological preparations > Anti-infective agents","","Other specified conjunctivitis","","Added","nan","who.int"
"netilmicin","Ophthalmological preparations > Anti-infective agents","","Infectious blepharitis","","Added","nan","who.int"
"nevirapine","Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors","Oral > Liquid: 50 mg per 5 mL oral solution
Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AG01","who.int"
"niclosamide","Intestinal anthelminthics","Oral > Solid: 500 mg tablet (chewable)","Hymenolepiasis","","Added","P02DA01","who.int"
"niclosamide","Intestinal anthelminthics","Oral > Solid: 500 mg tablet (chewable)","Diphyllobothriasis","","Added","P02DA01","who.int"
"niclosamide","Intestinal anthelminthics","Oral > Solid: 500 mg tablet (chewable)","Taeniasis due to Taenia saginata","","Added","P02DA01","who.int"
"niclosamide","Intestinal anthelminthics","Oral > Solid: 500 mg tablet (chewable)","Taeniasis due to Taenia solium","","Added","P02DA01","who.int"
"nicotinamide","Vitamins and minerals","Oral > Solid: 50 mg","Pellagra","","Added","A11HA01","who.int"
"nifedipine","Antioxytocics (tocolytics)","Oral > Solid: 10 mg (immediate-release)","Preterm labour without delivery","","Added","C08CA05","who.int"
"nifedipine","Antianginal medicines","Oral > Solid: 10 mg","Angina pectoris","","Removed","C08CA05","who.int"
"nifedipine","Antihypertensive medicines","Oral > Solid: 10 mg tablet; sustained-release formulations","Essential hypertension","","Removed","C08CA05","who.int"
"nifurtimox","Medicines for the treatment of 2nd stage African trypanosomiasis","Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)","African trypanosomiasis","","Added","P01CC01","who.int"
"nifurtimox","American trypanosomiasis","Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)","Chagas disease","","Added","P01CC01","who.int"
"nilotinib","Targeted therapies","Oral > Solid: 150 mg capsule; 200 mg capsule","Chronic myeloid leukaemia, not elsewhere classified","","Added","L01EA03","who.int"
"nilutamide","Hormones and antihormones","","Malignant neoplasms of prostate","","Added","nan","who.int"
"nitrous oxide","General anaesthetics and oxygen > Inhalational medicines","Respiratory > Inhalation: ","Anaesthetics and therapeutic gases","","Added","N01AX13","who.int"
"nivolumab","Immunomodulators","Parenteral > General injections > IV: 10 mg per  mL concentrate solution for infusion","Other specified malignant neoplasms of bronchus or lung","","Removed","L01FF01","who.int"
"nivolumab","Immunomodulators","Parenteral > General injections > IV: 10 mg per  mL concentrate solution for infusion","Melanoma of skin","","Added","L01FF01","who.int"
"norethisterone","Oral hormonal contraceptives","Oral > Solid: 350 µg","Contact with health services for contraceptive management","","Removed","G03AC01","who.int"
"norethisterone","Progestogens","Oral > Solid: 5 mg
","Excessive menstruation with irregular cycle","","Removed","G03DC02","who.int"
"norethisterone","Progestogens","Oral > Solid: 5 mg
","Excessive menstruation with irregular cycle","","Added","nan","who.int"
"norethisterone enantate","Injectable hormonal contraceptives","Parenteral > General injections > IM: 200 mg per  mL in 1 mL ampoule oily solution","Contact with health services for reasons associated with reproduction","","Added","G03AC01","who.int"
"normal immunoglobulin","Human immunoglobulins","Parenteral > General injections > IV: 5% protein solution; 10% protein solution
Parenteral > General injections > IM: 16% protein solution
Parenteral > General injections > SC: 15% protein solution; 16% protein solution","Primary immunodeficiencies","","Added","nan","who.int"
"normal immunoglobulin","Human immunoglobulins","Parenteral > General injections > IV: 5% protein solution; 10% protein solution
Parenteral > General injections > IM: 16% protein solution
Parenteral > General injections > SC: 15% protein solution; 16% protein solution","Mucocutaneous lymph node syndrome","","Added","nan","who.int"
"normal immunoglobulin","Human immunoglobulins","Parenteral > General injections > IV: 5% protein solution; 10% protein solution
Parenteral > General injections > IM: 16% protein solution
Parenteral > General injections > SC: 15% protein solution; 16% protein solution","Langerhans cell histiocytosis","","Added","J06BA02","who.int"
"nystatin","Antifungal medicines","Oral > Liquid: 100000 IU per  mL
Local > Topical > Other: 100000 IU pessary
Oral > Solid > dosage form: 500000 IU
Oral > Solid > lozenge: 100000 IU","Candidosis","","Added","A07AA02","who.int"
"ocrelizumab","Medicines for multiple sclerosis","Parenteral > General injections > IV: 30 mg per  mL in 10 mL vial
Parenteral > General injections > IV: 30 mg per  mL in 10 vial concentrate for solution","Relapsing-remitting multiple sclerosis","","Removed","L03AX13","who.int"
"ocrelizumab","Medicines for multiple sclerosis","Parenteral > General injections > IV: 30 mg per  mL in 10 mL vial
Parenteral > General injections > IV: 30 mg per  mL in 10 vial concentrate for solution","Multiple sclerosis","","Removed","L04AA36","who.int"
"ofloxacin","Antituberculosis medicines","Oral > Solid: 200 mg; 400 mg","Multi-drug resistant Mycobacterium tuberculosis","","Removed","J01MA01","who.int"
"ofloxacin","Ear, nose and throat medicines [c]","","Infectious diseases of external ear","","Added","nan","who.int"
"ofloxacin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 0.3%","Other specified conjunctivitis","","Added","S01AE01","who.int"
"ofloxacin","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 0.3%","Infectious keratitis","","Added","S01AE01","who.int"
"omadacycline","Reserve group antibiotics","Parenteral > General injections > IV: 100 mg lyophilized powder for injection
Oral > Solid: 300 mg","Methicillin resistant Staphylococcus aureus","","Removed","J01AA15","who.int"
"ombitasvir + paritaprevir + ritonavir","Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet","Chronic hepatitis C","","Removed","J05AP53","who.int"
"omeprazole","Antiulcer medicines","Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
Oral > Solid: 10 mg; 20 mg; 40 mg
Parenteral > General injections > IV: 40 mg in vial","Peptic ulcer, site unspecified","","Added","A02BC01","who.int"
"omeprazole","Antiulcer medicines","Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
Oral > Solid: 10 mg; 20 mg; 40 mg
Parenteral > General injections > IV: 40 mg in vial","Gastro-oesophageal reflux disease","","Added","A02BC01","who.int"
"omeprazole","Antiulcer medicines","Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
Oral > Solid: 10 mg; 20 mg; 40 mg
Parenteral > General injections > IV: 40 mg in vial","Gastrointestinal bleeding","","Added","A02BC01","who.int"
"ondansetron","Medicines for other common symptoms in palliative care","Parenteral > General injections > IV: 2 mg per  mL in 2 mL ampoule (ondansetron base, as hydrochloride)
Oral > Liquid: 4 mg per 5 mL (ondansetron base)
Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)","Palliative care","","Added","A04AA01","who.int"
"ondansetron","Antiemetic medicines","Parenteral > General injections > IV: 2 mg per  mL in 2 mL ampoule (ondansetron base, as hydrochloride)
Oral > Liquid: 4 mg per 5 mL (ondansetron base)
Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)","Nausea or vomiting","","Added","A04AA01","who.int"
"oral rehydration salts","Oral rehydration","Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L","Diarrhoea","","Added","A07CA","who.int"
"oral rehydration salts","Solutions correcting water, electrolyte and acid-base disturbances > Oral","Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L","Other specified disorders of fluid, electrolyte or acid-base balance","","Added","A07CA","who.int"
"oral rehydration salts - zinc sulfate","Medicines used in diarrhoea","Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)","Diarrhoea","","Added","A07CA","who.int"
"oseltamivir","Other antivirals","Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)","Influenza due to identified seasonal influenza virus","","Added","J05AH02","who.int"
"oxaliplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial","Malignant neoplasm metastasis in large intestine","","Added","L01XA03","who.int"
"oxaliplatin","Cytotoxic medicines","Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial","Malignant neoplasms of colon","","Added","L01XA03","who.int"
"oxamniquine","Antischistosomals and other antitrematode medicines","Oral > Liquid: 250 mg per 5 mL
Oral > Solid: 250 mg capsule","Schistosomiasis due to Schistosoma mansoni","","Added","P02BA02","who.int"
"oxazolindinones","Reserve group antibiotics",".","Other specified bacterial diseases","","Removed","nan","who.int"
"oxycodone","Opioid analgesics","","Pain","","Added","nan","who.int"
"oxygen","General anaesthetics and oxygen > Inhalational medicines","Respiratory > Inhalation: (medical gas)","Anaesthetics and therapeutic gases","","Added","V03AN01","who.int"
"oxygen","Medical gases","Respiratory > Inhalation: ","Respiratory failure as acute or chronic","","Added","V03AN01","who.int"
"oxytetracycline","Ophthalmological preparations > Anti-infective agents","","Other specified conjunctivitis","","Added","nan","who.int"
"oxytetracycline","Ophthalmological preparations > Anti-infective agents","","Infectious keratitis","","Added","nan","who.int"
"oxytetracycline","Ophthalmological preparations > Anti-infective agents","","Infectious blepharitis","","Added","nan","who.int"
"oxytetracycline","Ophthalmological preparations > Anti-infective agents","","Trachoma","","Added","nan","who.int"
"oxytocin","Uterotonics","Parenteral > General injections > unspecified: 10 IU per  mL","Postpartum haemorrhage","","Added","H01BB02","who.int"
"p-aminosalicylate sodium","Antituberculosis medicines","Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04AA01","who.int"
"p-aminosalicylic acid","Antituberculosis medicines","Oral > Solid: 4 g granules in sachet","Multi-drug resistant Mycobacterium tuberculosis","","Removed","J04AA01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Other specified malignant neoplasms of the ovary","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Other specified malignant neoplasms of bronchus or lung","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Malignant neoplasms of nasopharynx","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Kaposi sarcoma of unspecified primary site","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Other specified malignant neoplasms of breast","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Other specified carcinomas of ovary","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Malignant neoplasms of breast","","Added","L01CD01","who.int"
"paclitaxel","Cytotoxic medicines","Parenteral > General injections > IV: 6 mg per  mL","Malignant neoplasms of cervix uteri","","Added","L01CD01","who.int"
"palonosetron","Medicines for other common symptoms in palliative care","","Palliative care","","Added","nan","who.int"
"palonosetron","Antiemetic medicines","","Nausea or vomiting","","Added","nan","who.int"
"pancreatic enzymes","Pancreatic enzymes","Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.","Enzyme intestinal","","Added","A09AA02","who.int"
"paracetamol (acetaminophen)","Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)","Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
Local > Rectal > Suppository: 100 mg; 250 mg
Oral > Solid > dispersible tablet: 100 mg; 250 mg
Oral > Solid > tablet: 250 mg; 325 mg; 500 mg","Pain","","Added","N02BE01","who.int"
"paracetamol (acetaminophen)","Antimigraine medicines > For treatment of acute attack","Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
Local > Rectal > Suppository: 250 mg
Oral > Solid > dispersible tablet: 100 mg; 250 mg
Oral > Solid > tablet: 250 mg; 325 mg; 500 mg","Migraine","","Added","N02BE01","who.int"
"paromomycin","Antileishmaniasis medicines","Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)","Visceral leishmaniasis","","Added","A07AA06","who.int"
"paromomycin","Antiamoebic and antigiardiasis medicines","Oral > Liquid: 125 mg per 5 mL as sulfate
Oral > Solid: 250 mg as sulfate","Amoebiasis","","Removed","A07AA06","who.int"
"pegaspargase","Cytotoxic medicines","Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection","Lymphoid leukaemia, not elsewhere classified","","Added","L01XX24","who.int"
"pegylated interferon alfa (2a)","Medicines for hepatitis C > Other antivirals for hepatitis C","Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe","Chronic hepatitis C","","Removed","L03AB11","who.int"
"pegylated interferon alfa (2b)","Medicines for hepatitis C > Other antivirals for hepatitis C","Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe","Chronic hepatitis C","","Removed","L03AB10","who.int"
"pembrolizumab","Immunomodulators","","Melanoma of skin","","Added","nan","who.int"
"penicillamine","Antidotes and other substances used in poisonings > Specific","Oral > Solid: 250 mg","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","M01CC01","who.int"
"penicillamine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 250 mg","Rheumatoid arthritis, serology unspecified","","Added","M01CC01","who.int"
"pentamidine","Antileishmaniasis medicines","Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)","Visceral leishmaniasis","","Removed","P01CX01","who.int"
"pentamidine","Antipneumocystosis and antitoxoplasmosis medicines","Oral > Solid: 200 mg tablet; 300 mg tablet","Pneumocystosis","","Added","P01CX01","who.int"
"pentamidine","Medicines for the treatment of 1st stage African trypanosomiasis","Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection","African trypanosomiasis","","Added","P01CX01","who.int"
"permethrin","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 1%
Local > Topical > Cream: 5%","Pediculosis corporis","","Added","P03AC04","who.int"
"permethrin","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 1%
Local > Topical > Cream: 5%","Pediculosis capitis","","Added","P03AC04","who.int"
"permethrin","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Lotion: 1%
Local > Topical > Cream: 5%","Scabies","","Added","P03AC04","who.int"
"pertussis vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against pertussis alone","","Added","J07AJ02","who.int"
"pertuzumab","Targeted therapies","Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution","Carcinoma of breast, specialised type","","Removed","L01FD02","who.int"
"phenobarbital","Antiseizure medicines","Oral > Liquid: 15 mg per 5 mL
Oral > Solid: 15 to 100 mg
Parenteral > General injections > IV: 200 mg per  mL (phenobarbital sodium); 30 mg per  mL (phenobarbital sodium); 60 mg per  mL (phenobarbital sodium)","Epilepsy or seizures","","Added","N03AA02","who.int"
"phenobarbital","Antiseizure medicines","Oral > Liquid: 15 mg per 5 mL
Oral > Solid: 15 to 100 mg
Parenteral > General injections > IV: 200 mg per  mL (phenobarbital sodium); 30 mg per  mL (phenobarbital sodium); 60 mg per  mL (phenobarbital sodium)","Status epilepticus","","Added","N03AA02","who.int"
"phenoxymethylpenicillin","Access group antibiotics","Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)","","Added","J01CE02","who.int"
"phenoxymethylpenicillin","Access group antibiotics","Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","Periapical abscess without sinus","","Added","J01CE02","who.int"
"phenoxymethylpenicillin","Access group antibiotics","Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","Acute pharyngitis","","Added","J01CE02","who.int"
"phenoxymethylpenicillin","Access group antibiotics","Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)","Bacterial infection of unspecified site","","Removed","J01CE02","who.int"
"phenytoin","Antiseizure medicines","Oral > Liquid: 30 mg per 5 mL (phenytoin)
Parenteral > General injections > unspecified: 50 mg per  mL in vial (phenytoin sodium)
Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)","Epilepsy or seizures","","Added","N03AB02","who.int"
"phytomenadione","Medicines affecting coagulation","Parenteral > General injections > IV: 10 mg per  mL in ampoule; 1 mg per  mL in ampoule
Oral > Solid: 10 mg tablet","Haemorrhagic disorder due to other specified circulating anticoagulants","","Added","B02BA01","who.int"
"phytomenadione","Medicines affecting coagulation","Parenteral > General injections > IV: 10 mg per  mL in ampoule; 1 mg per  mL in ampoule
Oral > Solid: 10 mg tablet","Haemorrhagic or haematological disorders of fetus or newborn","","Added","B02BA01","who.int"
"pilocarpine","Ophthalmological preparations > Miotics and antiglaucoma medicines","Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)","Acute angle closure with pupillary block","","Added","S01EB01","who.int"
"pilocarpine","Ophthalmological preparations > Miotics and antiglaucoma medicines","Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)","Ocular hypertension","","Added","S01EB01","who.int"
"pilocarpine","Ophthalmological preparations > Miotics and antiglaucoma medicines","Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)","Primary open-angle glaucoma","","Added","S01EB01","who.int"
"piperacillin + tazobactam","Watch group antibiotics","Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","Other specified pneumonia (Hospital-acquired pneumonia)","","Added","J01CR05","who.int"
"piperacillin + tazobactam","Watch group antibiotics","Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","Peritonitis (severe)","","Added","J01CR05","who.int"
"piperacillin + tazobactam","Watch group antibiotics","Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","Neutropenia (high-risk)","","Added","J01CR05","who.int"
"piperacillin + tazobactam","Watch group antibiotics","Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection","Peritoneal abscess (severe)","","Added","J01CR05","who.int"
"platelets","Blood and blood components","Parenteral > General injections > IV: ","Blood transfusion without reported diagnosis","","Added","B05AX02","who.int"
"plazomicin","Reserve group antibiotics","Parenteral > General injections > IV: 500 mg per 10 mL (Injection)","Carbapenem resistant Acinetobacter baumannii","","Added","J01GB14","who.int"
"plazomicin","Reserve group antibiotics","Parenteral > General injections > IV: 500 mg per 10 mL (Injection)","Carbapenem-resistant Pseudomonas aeruginosa","","Added","J01GB14","who.int"
"plazomicin","Reserve group antibiotics","Parenteral > General injections > IV: 500 mg per 10 mL (Injection)","Carbapenem resistant Enterobacterales","","Added","J01GB14","who.int"
"pneumococcal vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against single bacterial diseases","","Added","J07AL01","who.int"
"podophyllotoxin","Dermatological medicines > Medicines affecting skin differentiation and proliferation","","Anogenital warts","","Added","nan","who.int"
"podophyllotoxin","Dermatological medicines > Medicines affecting skin differentiation and proliferation","","Plantar warts","","Added","nan","who.int"
"podophyllum resin","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Solution: 10 to 25%","Anogenital warts","","Added","D06BB04","who.int"
"podophyllum resin","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Solution: 10 to 25%","Plantar warts","","Added","D06BB04","who.int"
"poliomyelitis vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against poliomyelitis","","Added","J07BF01","who.int"
"poliomyelitis vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against poliomyelitis","","Added","J07BF02","who.int"
"poliomyelitis vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against poliomyelitis","","Added","J07BF03","who.int"
"poliomyelitis vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against poliomyelitis","","Added","J07BF04","who.int"
"polygeline","Plasma substitutes","Parenteral > General injections > IV: 3.5% injectable solution
Parenteral > General injections > IV: 3.5% in solution","Hypovolaemia","","Added","nan","who.int"
"polygeline","Plasma substitutes","Parenteral > General injections > IV: 3.5% injectable solution
Parenteral > General injections > IV: 3.5% in solution","Hypovolaemia","","Removed","nan","who.int"
"polymyxins","Reserve group antibiotics",".","Other specified bacterial diseases","","Removed","nan","who.int"
"potassium chloride","Solutions correcting water, electrolyte and acid-base disturbances > Oral","Oral > Liquid: powder for solution","Hypokalaemia","","Added","A12BA01","who.int"
"potassium chloride","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)","Hypokalaemia","","Added","B05XA01","who.int"
"potassium ferric hexacyanoferrate","Antidotes and other substances used in poisonings > Specific","Oral > Solid: Powder for oral administration","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","V03AB31","who.int"
"potassium iodide","Antifungal medicines","Local > Topical > Solution: Saturated solution","Sporotrichosis","","Added","nan","who.int"
"potassium iodide","Thyroid hormones and antithyroid medicines","Oral > Solid: 60 mg","Thyrotoxicosis","","Added","V03AB21","who.int"
"potassium permanganate","Dermatological medicines > Anti-infective medicines","Local > Topical > Solution: aqueous solution: 1:10 000","Tropical phagedaenic ulcer","","Added","D08AX06","who.int"
"potassium permanganate","Dermatological medicines > Anti-infective medicines","Local > Topical > Solution: aqueous solution: 1:10 000","Pemphigus","","Added","D08AX06","who.int"
"potassium permanganate","Dermatological medicines > Anti-infective medicines","Local > Topical > Solution: aqueous solution: 1:10 000","Other specified pyogenic bacterial infection of skin and subcutaneous tissue","","Added","D08AX06","who.int"
"potassium permanganate","Dermatological medicines > Anti-infective medicines","Local > Topical > Solution: aqueous solution: 1:10 000","Impetigo","","Added","D08AX06","who.int"
"povidone iodine","Antiseptics","Local > Topical > Solution: 10% (equivalent to 1% available iodine)","Povidone iodine","","Added","D08AG02","who.int"
"pralidoxime","Antidotes and other substances used in poisonings > Specific",".","Exposure to or harmful effects of undetermined intent of pesticides","","Removed","V03AB04","who.int"
"pramipexole","Antiseizure medicines","Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release","Parkinson disease","","Removed","N04BC05","who.int"
"pravastatin","Lipid-lowering agents","","Mixed hyperlipidaemia","","Added","nan","who.int"
"pravastatin","Lipid-lowering agents","","Coronary atherosclerosis","","Added","nan","who.int"
"praziquantel","Antischistosomals and other antitrematode medicines","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Paragonimiasis","","Added","P02BA01","who.int"
"praziquantel","Antischistosomals and other antitrematode medicines","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Clonorchiasis","","Added","P02BA01","who.int"
"praziquantel","Antischistosomals and other antitrematode medicines","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Opisthorchiasis","","Added","P02BA01","who.int"
"praziquantel","Antischistosomals and other antitrematode medicines","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Schistosomiasis","","Added","P02BA01","who.int"
"praziquantel","Intestinal anthelminthics","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Taeniasis due to Taenia saginata","","Added","P02BA01","who.int"
"praziquantel","Intestinal anthelminthics","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Taeniasis due to Taenia solium","","Added","P02BA01","who.int"
"praziquantel","Intestinal anthelminthics","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Diphyllobothriasis","","Added","P02BA01","who.int"
"praziquantel","Intestinal anthelminthics","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Hymenolepiasis","","Added","P02BA01","who.int"
"praziquantel","Cysticidal medicines","Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg","Cysticercosis of central nervous system","","Added","P02BA01","who.int"
"precipitated sulfur","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Ointment: ","Pthiriasis","","Added","nan","who.int"
"precipitated sulfur","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Ointment: ","Pediculosis corporis","","Added","nan","who.int"
"precipitated sulfur","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Ointment: ","Pediculosis capitis","","Added","nan","who.int"
"precipitated sulfur","Dermatological medicines > Scabicides and pediculicides","Local > Topical > Ointment: ","Scabies","","Added","nan","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Plasma cell myeloma","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Follicular lymphoma","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Lymphoid leukaemia, not elsewhere classified","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Malignant neoplasms of prostate","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Hodgkin lymphoma","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Diffuse large B-cell lymphomas","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Burkitt lymphoma including Burkitt leukaemia","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Anaplastic large cell lymphoma, ALK-negative","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Anaplastic large cell lymphoma, ALK-positive","","Added","H02AB06","who.int"
"prednisolone","Hormones and antihormones","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Langerhans cell histiocytosis","","Added","H02AB06","who.int"
"prednisolone","Anti-inflammatory medicines","Local > Rectal > Retention enema: 
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)","Crohn disease site","","Added","nan","who.int"
"prednisolone","Anti-inflammatory medicines","Local > Rectal > Retention enema: 
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)","Crohn disease site","","Added","A07EA01","who.int"
"prednisolone","Anti-inflammatory medicines","Local > Rectal > Retention enema: 
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)","Ulcerative colitis","","Added","A07EA01","who.int"
"prednisolone","Antiallergics and medicines used in anaphylaxis","Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg","Allergic or hypersensitivity conditions of unspecified type","","Added","H02AB06","who.int"
"prednisolone","Ophthalmological preparations > Anti-inflammatory agents","Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)","Scleritis","","Added","S01BA04","who.int"
"prednisolone","Ophthalmological preparations > Anti-inflammatory agents","Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)","Anterior uveitis","","Added","S01BA04","who.int"
"prednisone","Hormones and antihormones","","Plasma cell myeloma","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Follicular lymphoma","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Lymphoid leukaemia, not elsewhere classified","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Malignant neoplasms of prostate","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Hodgkin lymphoma","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Diffuse large B-cell lymphomas","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Anaplastic large cell lymphoma, ALK-negative","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Anaplastic large cell lymphoma, ALK-positive","","Added","nan","who.int"
"prednisone","Hormones and antihormones","","Langerhans cell histiocytosis","","Added","nan","who.int"
"prednisone","Antiallergics and medicines used in anaphylaxis","","Allergic or hypersensitivity conditions of unspecified type","","Added","nan","who.int"
"pretomanid","Antituberculosis medicines","Oral > Solid > tablet: 200 mg","Multi-drug resistant Mycobacterium tuberculosis","","Added","J04AK08","who.int"
"primaquine","Antimalarial medicines > For curative treatment","Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)","Malaria due to Plasmodium ovale","","Added","P01BA03","who.int"
"primaquine","Antimalarial medicines > For curative treatment","Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)","Malaria due to Plasmodium vivax","","Added","P01BA03","who.int"
"probenecid","Medicines used to treat gout","Oral > Solid: 500 mg","Gout","","Removed","M04AB01","who.int"
"procainamide","Antiarrhythmic medicines","Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule (hydrochloride)
Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)","Cardiac arrhythmia","","Removed","C01BA02","who.int"
"procaine benzylpenicillin","Access group antibiotics","Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection","Congenital syphilis [children]","","Added","J01CE09","who.int"
"procaine benzylpenicillin","Access group antibiotics","Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection","Syphilis","","Added","J01CE09","who.int"
"procarbazine","Cytotoxic medicines","Oral > Solid: 50 mg (as hydrochloride)","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01XB01","who.int"
"procarbazine","Cytotoxic medicines","Oral > Solid: 50 mg (as hydrochloride)","Hodgkin lymphoma","","Added","L01XB01","who.int"
"progesterone vaginal ring","Intravaginal contraceptives","Local > Vaginal > vaginal ring: 2.074 g micronized progesterone","Contact with health services for contraceptive management","","Added","G03DA04","who.int"
"proguanil","Antimalarial medicines > For chemoprevention","Oral > Solid: 100 mg tablet (hydrochloride)","Malaria due to Plasmodium falciparum","","Added","P01BB01","who.int"
"promethazine","Antiemetic medicines","Oral > Liquid: 5 mg per 5 mL (hydrochloride)
Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
Parenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule","Nausea or vomiting","","Removed","R06AD02","who.int"
"propanol","Antiseptics","","Denatured alcohol","","Added","nan","who.int"
"propofol","General anaesthetics and oxygen > Injectable medicines","Parenteral > General injections > IV: 10 mg per  mL; 20 mg per  mL","Anaesthetics and therapeutic gases","","Added","N01AX10","who.int"
"propranolol","Antihypertensive medicines","Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)","Essential hypertension","","Removed","C07AA05","who.int"
"propranolol","Antianginal medicines","Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)","Angina pectoris","","Removed","C07AA05","who.int"
"propranolol","Antiarrhythmic medicines","Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)","Cardiac arrhythmia","","Removed","C07AA05","who.int"
"propranolol","Antimigraine medicines > For prophylaxis","Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)","Migraine","","Added","C07AA05","who.int"
"propylthiouracil","Thyroid hormones and antithyroid medicines","Oral > Solid: 50 mg","Thyrotoxicosis","","Added","H03BA02","who.int"
"prostaglandin e1","Medicines administered to the neonate [c]","Parenteral > General injections > IV: 0.5 mg per  mL in alcohol","Other specified congenital anomaly of great arteries including arterial duct","","Added","C01EA01","who.int"
"prostaglandin e2","Medicines administered to the neonate [c]","Parenteral > General injections > IV: 1 mg per  mL","Other specified congenital anomaly of great arteries including arterial duct","","Added","nan","who.int"
"prostaglandin e2","Medicines administered to the neonate [c]","Parenteral > General injections > IV: 1 mg per  mL","Other specified congenital anomaly of great arteries including arterial duct","","Removed","G02AD02","who.int"
"protamine sulfate","Medicines affecting coagulation","Parenteral > General injections > IV: 10 mg per  mL in 5 mL ampoule","Haemorrhagic disorder due to other specified circulating anticoagulants","","Added","V03AB14","who.int"
"protionamide","Antituberculosis medicines","","Multi-drug resistant Mycobacterium tuberculosis","","Added","nan","who.int"
"pyrantel","Intestinal anthelminthics","Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","Ascariasis","","Added","P02CC01","who.int"
"pyrantel","Intestinal anthelminthics","Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","Enterobiasis","","Added","P02CC01","who.int"
"pyrantel","Intestinal anthelminthics","Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","Trichuriasis","","Added","P02CC01","who.int"
"pyrantel","Intestinal anthelminthics","Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)","Hookworm diseases","","Added","P02CC01","who.int"
"pyrazinamide","Antituberculosis medicines","Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg","Tuberculosis","","Added","J04AK01","who.int"
"pyridostigmine","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
Oral > Solid: 60 mg (pyridostigmine bromide)","Myasthenia gravis","","Added","N07AA02","who.int"
"pyridoxine","Vitamins and minerals","Oral > Solid: 25 mg (hydrochloride)","Vitamin B6 deficiency","","Added","A11HA02","who.int"
"pyridoxine","Vitamins and minerals","Oral > Solid: 25 mg (hydrochloride)","Sideroblastic anaemia","","Added","A11HA02","who.int"
"pyridoxine","Vitamins and minerals","Oral > Solid: 25 mg (hydrochloride)","Other specified polyneuropathy","","Added","A11HA02","who.int"
"pyrimethamine","Antipneumocystosis and antitoxoplasmosis medicines","Oral > Solid: 25 mg","Toxoplasmosis","","Added","P01BD01","who.int"
"quinidine","Antiarrhythmic medicines","Oral > Solid: 200 mg (sulfate)","Cardiac arrhythmia","","Removed","C01BA01","who.int"
"quinine","Antimalarial medicines > For curative treatment","Parenteral > General injections > IV: 300 mg per  mL in 2 mL ampoule (quinine hydrochloride)
Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)","Malaria due to Plasmodium falciparum","","Added","P01BC01","who.int"
"rabies vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against rabies","","Added","J07BG01","who.int"
"raltegravir","Antiretrovirals > Integrase inhibitors","Oral > Liquid: 100 mg granules for oral suspension
Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AJ01","who.int"
"ranibizumab","Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations",".","Retinal venous occlusions","","Removed","S01LA04","who.int"
"ranibizumab","Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations",".","Diabetic macular oedema","","Removed","S01LA04","who.int"
"ranibizumab","Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations",".","Degenerative high myopia","","Removed","S01LA04","who.int"
"ranibizumab","Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations",".","Age related macular degeneration","","Removed","S01LA04","who.int"
"ranitidine","Antiulcer medicines","Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule (as hydrochloride)","Gastro-oesophageal reflux disease","","Added","A02BA02","who.int"
"ranitidine","Antiulcer medicines","Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule (as hydrochloride)","Peptic ulcer, site unspecified","","Added","A02BA02","who.int"
"rasburicase","Supportive medicines","Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution","Tumour lysis syndrome","","Added","V03AF07","who.int"
"ravidasvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid > tablet: 200 mg","Chronic hepatitis C","","Added","nan","who.int"
"realgar-indigo naturalis formulation","Cytotoxic medicines","Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)","Acute myeloid leukaemia with recurrent genetic abnormalities","","Added","nan","who.int"
"red blood cells","Blood and blood components","Parenteral > General injections > IV: ","Blood transfusion without reported diagnosis","","Added","B05AX01","who.int"
"retinol","Vitamins and minerals","Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
Oral > Liquid: 100000 IU per  mL (as palmitate) oral oily solution in multidose dispenser
Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule","Vitamin A deficiency","","Added","A11CA01","who.int"
"ribavirin","Other antivirals","Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg","Viral haemorrhagic fever, not elsewhere classified","","Added","J05AB04","who.int"
"ribavirin","Medicines for hepatitis C > Other antivirals for hepatitis C","Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg","Chronic hepatitis C","","Added","J05AP01","who.int"
"riboflavin","Vitamins and minerals","Oral > Solid: 5 mg","Vitamin B2 deficiency","","Added","A11HA04","who.int"
"rifabutin","Antituberculosis medicines","Oral > Solid: 150 mg","Tuberculosis","","Added","J04AB04","who.int"
"rifampicin","Antituberculosis medicines","Oral > Liquid: 20 mg per  mL
Oral > Solid: 150 mg; 300 mg
Parenteral > General injections > IV: 600 mg in vial powder for injection","Tuberculosis","","Added","J04AB02","who.int"
"rifampicin","Antituberculosis medicines","Oral > Liquid: 20 mg per  mL
Oral > Solid: 150 mg; 300 mg
Parenteral > General injections > IV: 600 mg in vial powder for injection","Other specified tuberculosis","","Removed","J04AB02","who.int"
"rifampicin","Antileprosy medicines","Oral > Liquid: 20 mg per  mL
Oral > Solid: 150 mg; 300 mg","Leprosy","","Added","J04AB02","who.int"
"rifapentine","Antituberculosis medicines","Oral > Solid: 150 mg tablet; 300 mg tablet","Tuberculosis","","Added","J04AB05","who.int"
"rifapentine","Antituberculosis medicines","Oral > Solid: 150 mg tablet; 300 mg tablet","Latent tuberculosis","","Added","J04AB05","who.int"
"risdiplam","Medicines for diseases of the nervous system","Oral > Liquid: 0.75 mg per  mL powder for oral liquid","Spinal muscular atrophy","","Removed","M09AX10","who.int"
"ritonavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AE03","who.int"
"rituximab","Targeted therapies","Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial","Follicular lymphoma","","Added","L01FA01","who.int"
"rituximab","Targeted therapies","Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial","Chronic lymphocytic leukaemia or small lymphocytic lymphoma","","Added","L01FA01","who.int"
"rituximab","Targeted therapies","Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial","Diffuse large B-cell lymphomas","","Added","L01FA01","who.int"
"rituximab","Medicines for multiple sclerosis","Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial","Multiple sclerosis","","Added","L01FA01","who.int"
"rivaroxaban","Medicines affecting coagulation","","Venous thromboembolism","","Added","nan","who.int"
"rivaroxaban","Medicines affecting coagulation","","Other specified atrial fibrillation","","Added","nan","who.int"
"ropinirole","Antiseizure medicines","Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release","Parkinson disease","","Removed","N04BC04","who.int"
"rotavirus vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BH01","who.int"
"rotavirus vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BH02","who.int"
"rubella vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against rubella alone","","Added","J07BJ01","who.int"
"salbutamol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Parenteral > General injections > IV: 50 µg per  mL in 5 mL ampoule (as sulfate)
Respiratory > Inhalation > aerosol: 100 µg per  dose (as sulfate); 100 µg per  dose (as sulfate) metered-dose inhaler
Respiratory > Inhalation > solution: 5 mg per  mL (as sulfate) for use in nebulizers","Chronic obstructive pulmonary disease","","Added","R03AC02","who.int"
"salbutamol","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Parenteral > General injections > IV: 50 µg per  mL in 5 mL ampoule (as sulfate)
Respiratory > Inhalation > aerosol: 100 µg per  dose (as sulfate); 100 µg per  dose (as sulfate) metered-dose inhaler
Respiratory > Inhalation > solution: 5 mg per  mL (as sulfate) for use in nebulizers","Asthma","","Added","R03AC02","who.int"
"salicylic acid","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Solution: 5%","Seborrhoeic dermatitis","","Added","D01AE12","who.int"
"salicylic acid","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Solution: 5%","Psoriasis of unspecified type","","Added","D01AE12","who.int"
"salicylic acid","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Solution: 5%","Ichthyoses","","Added","D01AE12","who.int"
"saquinavir","Antiretrovirals > Protease inhibitors","Oral > Solid: 200 mg; 500 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AE01","who.int"
"selenium sulfide","Dermatological medicines > Antifungal medicines","Local > Topical > Suspension: 2% detergent-based","Seborrhoeic dermatitis","","Added","D01AE13","who.int"
"selenium sulfide","Dermatological medicines > Antifungal medicines","Local > Topical > Suspension: 2% detergent-based","Pityriasis versicolor","","Added","D01AE13","who.int"
"senna","Medicines for other common symptoms in palliative care","Oral > Liquid: 7.5 mg per 5 mL oral liquid","Palliative care","","Added","A06AB06","who.int"
"senna","Laxatives","Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)","Constipation","","Added","A06AB06","who.int"
"sevoflurane","General anaesthetics and oxygen > Inhalational medicines","Respiratory > Inhalation > liquid: ","Anaesthetics and therapeutic gases","","Added","N01AB08","who.int"
"silver diamine fluoride","Dental medicines and preparations","Local > Dental > Solution: 38% w/v","Dental caries","","Added","nan","who.int"
"silver nitrate","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Solution (eye drops): 1%","Neonatal conjunctivitis or dacryocystitis","","Removed","D08AL01","who.int"
"silver sulfadiazine","Dermatological medicines > Anti-infective medicines","Local > Topical > Cream: 1%","Burns","","Added","D06BA01","who.int"
"simeprevir","Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations","Oral > Solid: 150 mg","Chronic hepatitis C","","Removed","J05AP05","who.int"
"simvastatin","Lipid-lowering agents","Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg","Mixed hyperlipidaemia","","Added","C10AA01","who.int"
"simvastatin","Lipid-lowering agents","Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg","Coronary atherosclerosis","","Added","C10AA01","who.int"
"simvastatin","Medicines for endocrine disorders","Oral > Solid: 20 mg","Polycystic ovary syndrome","","Removed","C10AA01","who.int"
"smallpox vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Removed","J07BX01","who.int"
"snake antivenom","Immunologicals > Sera, immunoglobulins and monoclonal antibodies",".","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Removed","J06AA03","who.int"
"sodium calcium edetate","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 200 mg per  mL in 5 mL ampoule","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","V03AB03","who.int"
"sodium chloride","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)","Other specified disorders of fluid, electrolyte or acid-base balance","","Added","B05XA03","who.int"
"sodium hydrogen carbonate","Solutions correcting water, electrolyte and acid-base disturbances > Parenteral","Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)","Acidosis","","Added","B05XA02","who.int"
"sodium nitrite","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 30 mg per  mL in 10 mL ampoule","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","V03AB08","who.int"
"sodium nitroprusside","Antihypertensive medicines","Parenteral > General injections > IV: 50 mg in ampoule powder for infusion","Hypertensive crisis","","Added","C02DD01","who.int"
"sodium stibogluconate","Antileishmaniasis medicines","Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial","Visceral leishmaniasis","","Added","P01CB02","who.int"
"sodium stibogluconate","Antileishmaniasis medicines","Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial","Mucocutaneous leishmaniasis","","Added","P01CB02","who.int"
"sodium stibogluconate","Antileishmaniasis medicines","Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial","Cutaneous leishmaniasis","","Added","P01CB02","who.int"
"sodium thiosulfate","Dermatological medicines > Antifungal medicines","Local > Topical > Solution: 15%","Pityriasis versicolor","","Added","V03AB06","who.int"
"sodium thiosulfate","Antidotes and other substances used in poisonings > Specific","Parenteral > General injections > IV: 250 mg per  mL in 50 mL ampoule","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","V03AB06","who.int"
"sofosbuvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid: 400 mg; 200 mg","Chronic hepatitis C","","Added","J05AP08","who.int"
"sofosbuvir + velpatasvir","Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations","Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet","Chronic hepatitis C","","Added","J05AP55","who.int"
"spectinomycin","Access group antibiotics","Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection","Gonococcal infection","","Added","J01XX04","who.int"
"spectinomycin","Access group antibiotics","Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection","Bacterial infection of unspecified site","","Removed","J01XX04","who.int"
"spironolactone","Medicines used in heart failure","Oral > Solid: 25 mg","Heart failure","","Added","C03DA01","who.int"
"spironolactone","Diuretics","Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
Oral > Solid: 25 mg","Oedema","","Added","C03DA01","who.int"
"spironolactone","Diuretics","Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
Oral > Solid: 25 mg","Ascites","","Added","C03DA01","who.int"
"stavudine","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Liquid: 5 mg per 5 mL powder for oral solution
Oral > Solid: 15 mg; 20 mg; 30 mg","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Removed","J05AF04","who.int"
"streptokinase","Thrombolytic medicines","Parenteral > General injections > IV: 1.5 million IU in vial powder for injection","Acute myocardial infarction","","Added","B01AD01","who.int"
"streptomycin (injection)","Antituberculosis medicines","Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial","Multi-drug resistant Mycobacterium tuberculosis","","Added","J01GA01","who.int"
"succimer","Antidotes and other substances used in poisonings > Specific","Oral > Solid: 100 mg","Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified","","Added","nan","who.int"
"sulfacetamide","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 10% (sodium salt)","Other specified conjunctivitis","","Removed","S01AB04","who.int"
"sulfadiazine","Antipneumocystosis and antitoxoplasmosis medicines","Oral > Solid: 500 mg","Toxoplasmosis","","Added","J01EC02","who.int"
"sulfadiazine","Anti-infective medicines","Oral > Solid: 500 mg
Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)","Bacterial infection of unspecified site","","Removed","J01EC02","who.int"
"sulfadimidine","Anti-infective medicines","Oral > Liquid: 500 mg per 5 mL
Oral > Solid: 500 mg
Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)","Bacterial infection of unspecified site","","Removed","J01EB03","who.int"
"sulfadoxine + pyrimethamine","Antimalarial medicines > For curative treatment","Oral > Solid: 500 mg + 25 mg tablet","Malaria due to Plasmodium falciparum","","Added","P01BD51","who.int"
"sulfadoxine + pyrimethamine","Antimalarial medicines > For curative treatment","Oral > Solid: 500 mg + 25 mg tablet","Malaria due to Plasmodium vivax","","Added","P01BD51","who.int"
"sulfadoxine + pyrimethamine","Antimalarial medicines > For chemoprevention","Oral > Solid: 500 mg + 25 mg tablet
Oral > Solid: 250 mg + 12.5 mg tablet","Malaria due to Plasmodium falciparum","","Added","P01BD51","who.int"
"sulfadoxine + pyrimethamine","Antimalarial medicines > For chemoprevention","Oral > Solid: 500 mg + 25 mg tablet
Oral > Solid: 250 mg + 12.5 mg tablet","Malaria","","Added","P01BD51","who.int"
"sulfamethoxazole + trimethoprim","Access group antibiotics","Parenteral > General injections > IV: 80 mg + 16 mg per  mL in 10 mL ampoule; 80 mg + 16 mg per  mL in 5 mL ampoule
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet","Bacterial infection of unspecified site","","Removed","J01EE01","who.int"
"sulfamethoxazole + trimethoprim","Antipneumocystosis and antitoxoplasmosis medicines","Parenteral > General injections > IV: 80 mg + 16 mg per  mL in 5 mL ampoule; 80 mg + 16 mg per  mL in 10 mL ampoule
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
Oral > Solid > dispersible tablet: 100 mg + 20 mg","Pneumocystosis","","Added","J01EE01","who.int"
"sulfasalazine","Disease-modifying anti-rheumatic drugs (DMARDs)","Oral > Solid: 500 mg","Rheumatoid arthritis, serology unspecified","","Added","A07EC01","who.int"
"sulfasalazine","Anti-inflammatory medicines","Oral > Solid: 500 mg
Local > Rectal > Suppository: 500 mg
Local > Rectal > Retention enema: ","Crohn disease site","","Added","A07EC01","who.int"
"sulfasalazine","Anti-inflammatory medicines","Oral > Solid: 500 mg
Local > Rectal > Suppository: 500 mg
Local > Rectal > Retention enema: ","Ulcerative colitis","","Added","A07EC01","who.int"
"sumatriptan","Antimigraine medicines > For treatment of acute attack","Oral > Solid: 50 mg","Migraine","","Added","N02CC01","who.int"
"suramin sodium","Antifilarials","Parenteral > General injections > IV: 1 g in vial","Filariasis","","Removed","P01CX02","who.int"
"suramin sodium","Medicines for the treatment of 1st stage African trypanosomiasis","Parenteral > General injections > IV: 1 g in vial","African trypanosomiasis","","Added","P01CX02","who.int"
"surfactant","Medicines administered to the neonate [c]","Respiratory > Suspension: 80 mg per  mL for intratracheal instillation; 25 mg per  mL for intratracheal instillation","Respiratory distress syndrome of newborn","","Added","R07AA02","who.int"
"suxamethonium","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 50 mg per  mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial","Muscle relaxants","","Added","M03AB01","who.int"
"tacalcitol","Dermatological medicines > Medicines affecting skin differentiation and proliferation","","Psoriasis of unspecified type","","Added","nan","who.int"
"tacrolimus","Immunomodulators for non-malignant disease","Parenteral > General injections > IV: 5 mg per  mL in 1 mL vial
Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)","Failure or rejection of transplanted organs or tissues","","Added","L04AD02","who.int"
"tamoxifen","Hormones and antihormones","Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)","Other specified malignant neoplasms of breast","","Added","L02BA01","who.int"
"tamoxifen","Hormones and antihormones","Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)","Malignant neoplasms of breast","","Added","L02BA01","who.int"
"telmisartan + amlodipine","Antihypertensive medicines","Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg","Essential hypertension","","Added","C09DB04","who.int"
"telmisartan + hydrochlorothiazide","Antihypertensive medicines","Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg","Essential hypertension","","Added","C09DA07","who.int"
"tenofovir alafenamide","Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Solid: 25 mg","Chronic hepatitis B","","Removed","J05AF13","who.int"
"tenofovir disoproxil fumarate","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AF07","who.int"
"tenofovir disoproxil fumarate","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)","Contact with or exposure to human immunodeficiency virus","","Added","J05AF07","who.int"
"tenofovir disoproxil fumarate","Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors","Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)","Chronic hepatitis B","","Added","J05AF07","who.int"
"terbinafine","Dermatological medicines > Antifungal medicines","Local > Topical > Cream: 1% terbinafine hydrochloride
Local > Topical > Ointment: 1% terbinafine hydrochloride","Fungal infection of the skin","","Added","D01AE15","who.int"
"terbutaline","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Chronic obstructive pulmonary disease","","Added","nan","who.int"
"terbutaline","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Asthma","","Added","nan","who.int"
"terizidone","Antituberculosis medicines","","Multi-drug resistant Mycobacterium tuberculosis","","Added","nan","who.int"
"testosterone","Androgens","Parenteral > General injections > IM: 200 mg per  mL in 1 mL ampoule (enantate)","Testicular dysfunction or testosterone-related disorders","","Added","G03BA03","who.int"
"tetanus antitoxin","Immunologicals > Sera, immunoglobulins and monoclonal antibodies","Parenteral > General injections > IM: 50000 IU in vial","Tetanus","","Removed","J06AA02","who.int"
"tetanus vaccine","Recommendations for all immunization programmes","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against tetanus alone","","Added","J07AM01","who.int"
"tetracaine","Ophthalmological preparations > Local anaesthetics","Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)","Local anaesthetics","","Added","S01HA03","who.int"
"tetracycline","Access group antibiotics","Oral > Solid: 250 mg (hydrochloride)","Bacterial infection of unspecified site","","Removed","J01AA07","who.int"
"tetracycline","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","Neonatal conjunctivitis or dacryocystitis","","Removed","S01AA09","who.int"
"tetracycline","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","Other specified conjunctivitis","","Added","S01AA09","who.int"
"tetracycline","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","Infectious keratitis","","Added","S01AA09","who.int"
"tetracycline","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","Infectious blepharitis","","Added","S01AA09","who.int"
"tetracycline","Ophthalmological preparations > Anti-infective agents","Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)","Trachoma","","Added","S01AA09","who.int"
"thalidomide","Immunomodulators","Oral > Solid: 50 mg","Plasma cell myeloma","","Added","L04AX02","who.int"
"thiamine","Vitamins and minerals","Oral > Solid: 50 mg (hydrochloride)","Vitamin B1 deficiency","","Added","A11DA01","who.int"
"thiopental","General anaesthetics and oxygen > Injectable medicines","","Anaesthetics and therapeutic gases","","Added","nan","who.int"
"tick-borne encephalitis vaccine","Recommendations for certain regions","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against arthropod-borne viral encephalitis","","Added","J07BA01","who.int"
"tigecycline","Reserve group antibiotics","Parenteral > General injections > IV: 50 mg in vial powder for injection","Other specified bacterial diseases","","Removed","J01AA12","who.int"
"timolol","Ophthalmological preparations > Miotics and antiglaucoma medicines","Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)","Primary open-angle glaucoma","","Added","S01ED01","who.int"
"timolol","Ophthalmological preparations > Miotics and antiglaucoma medicines","Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)","Ocular hypertension","","Added","S01ED01","who.int"
"tinidazole","Antiamoebic and antigiardiasis medicines","","Amoebiasis","","Added","nan","who.int"
"tioguanine","Cytotoxic medicines","Oral > Solid: 40 mg","Lymphoid leukaemia, not elsewhere classified","","Added","L01BB03","who.int"
"tiotropium bromide","Antiasthmatic and medicines for chronic obstructive pulmonary disease","Respiratory > Inhalation > dry powder: 18 µg capsule
Respiratory > Inhalation > solution: 1.25 µg per  actuation; 2.5 µg per  actuation","Chronic obstructive pulmonary disease","","Added","R03BB04","who.int"
"tisagenlecleucel","Antineoplastics and supportive medicines","","Diffuse large B-cell lymphomas","","Removed","nan","who.int"
"tislelizumab","Immunomodulators","Parenteral > General injections > IV: 100 mg per 10 mL","Malignant neoplasms of urinary tract","","Removed","L01FF09","who.int"
"tislelizumab","Immunomodulators","Parenteral > General injections > IV: 100 mg per 10 mL","Hodgkin lymphoma","","Removed","L01FF09","who.int"
"tobramycin","Ophthalmological preparations > Anti-infective agents","","Other specified conjunctivitis","","Added","nan","who.int"
"tobramycin","Ophthalmological preparations > Anti-infective agents","","Infectious blepharitis","","Added","nan","who.int"
"tolbutamide","Oral hypoglycaemic agents","Oral > Solid: 500 mg","Type 2 diabetes mellitus","","Removed","A10BB03","who.int"
"torasemide","Medicines used in heart failure","","Heart failure","","Added","nan","who.int"
"torasemide","Diuretics","","Anuria or oliguria","","Added","nan","who.int"
"torasemide","Diuretics","","Oedema","","Added","nan","who.int"
"tramadol","Opioid analgesics","Oral > Liquid: 100 mg per  mL (hydrochloride)
Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
Parenteral > General injections > unspecified: 50 mg per  mL in 2 mL ampoule (hydrochloride)","Chronic cancer pain","","Removed","N02AX02","who.int"
"trametinib","Targeted therapies","Oral > Solid: 0.5 mg; 2 mg","Other specified melanoma of skin","","Removed","L01EE01","who.int"
"tranexamic acid","Medicines affecting coagulation","Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","Haemorrhage, not elsewhere classified","","Added","B02AA02","who.int"
"tranexamic acid","Other medicines administered to the mother","Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule","Postpartum haemorrhage","","Added","B02AA02","who.int"
"trastuzumab","Targeted therapies","Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection","Carcinoma of breast, specialised type","","Added","L01FD01","who.int"
"trastuzumab emtansine","Targeted therapies","Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection","Carcinoma of breast, specialised type","","Removed","L01FD03","who.int"
"triclabendazole","Antischistosomals and other antitrematode medicines","Oral > Solid > tablet: 250 mg (scored)","Fascioliasis","","Added","P02BX04","who.int"
"triclabendazole","Antischistosomals and other antitrematode medicines","Oral > Solid > tablet: 250 mg (scored)","Paragonimiasis","","Added","P02BX04","who.int"
"trihexyphenidyl","Antiseizure medicines","Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)","Parkinson disease","","Removed","N04AA01","who.int"
"trihexyphenidyl","Medicines for parkinsonism","","Parkinson disease","","Added","nan","who.int"
"trimethoprim","Access group antibiotics","Oral > Liquid: 50 mg per  mL
Oral > Solid: 100 mg; 200 mg","Infectious cystitis","","Added","J01EA01","who.int"
"triptorelin","Hormones and antihormones","","Malignant neoplasms of breast","","Added","nan","who.int"
"triptorelin","Hormones and antihormones","","Malignant neoplasms of prostate","","Added","nan","who.int"
"tropicamide","Diagnostic agents > Ophthalmic medicines","Local > Ophthalmological > Solution (eye drops): 0.5%","Cycloplegic drug","","Added","S01FA06","who.int"
"tropisetron","Medicines for other common symptoms in palliative care","","Palliative care","","Added","nan","who.int"
"tropisetron","Antiemetic medicines","","Nausea or vomiting","","Added","nan","who.int"
"tuberculin, purified protein derivative","Immunologicals > Diagnostic agents","Parenteral > Locoregional injections > Intradermal: ","Mycobacterial diseases","","Added","V04CF01","who.int"
"tubocurarine","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 10 mg per  mL in 1.5 mL ampoule (tubocurarine chloride)","Muscle relaxants","","Removed","M03AA02","who.int"
"typhoid vaccine","Recommendations for some high-risk populations","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against typhoid-paratyphoid alone","","Added","J07AP03","who.int"
"ulipristal","Oral hormonal contraceptives","Oral > Solid: 30 mg tablet (ulipristal acetate)","Contact with health services for postcoital contraception","","Added","G03AD02","who.int"
"umeclidinium","Antiasthmatic and medicines for chronic obstructive pulmonary disease","","Chronic obstructive pulmonary disease","","Added","nan","who.int"
"urea","Dermatological medicines > Medicines affecting skin differentiation and proliferation","Local > Topical > Cream: 10%; 5%
Local > Topical > Ointment: 10%; 5%","Xerosis cutis or asteatosis","","Added","D02AE01","who.int"
"valaciclovir","Antiherpes medicines","","Zoster","","Added","nan","who.int"
"valaciclovir","Antiherpes medicines","","Varicella","","Added","nan","who.int"
"valaciclovir","Antiherpes medicines","","Herpes simplex infections","","Added","nan","who.int"
"valganciclovir","Other antivirals","Oral > Liquid: 50 mg per  mL powder for oral solution
Oral > Solid: 450 mg Tablet","Cytomegaloviral retinitis","","Added","J05AB14","who.int"
"valproic acid (sodium valproate)","Antiseizure medicines","Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule; 100 mg per  mL in 3 mL ampoule","Epilepsy or seizures","","Added","N03AG01","who.int"
"valproic acid (sodium valproate)","Antiseizure medicines","Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule; 100 mg per  mL in 3 mL ampoule","Status epilepticus","","Added","N03AG01","who.int"
"valproic acid (sodium valproate)","Medicines for bipolar disorders","Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)","Bipolar or related disorders","","Added","N03AG01","who.int"
"vancomycin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection","Endophthalmitis","ceftazidime","Added","J01XA01","who.int"
"vancomycin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection","Endophthalmitis","ceftriaxone","Added","J01XA01","who.int"
"vancomycin","Watch group antibiotics","Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection","Methicillin resistant Staphylococcus aureus","","Removed","J01XA01","who.int"
"varenicline","Medicines for nicotine use disorders","Oral > Solid: 0.5 mg; 1 mg","Nicotine dependence","","Added","N07BA03","who.int"
"varicella vaccine","Recommendations for immunization programmes with certain characteristics","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BK01","who.int"
"vecuronium","Muscle relaxants (peripherally-acting) and cholinesterase inhibitors","Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)","Muscle relaxants","","Added","M03AC03","who.int"
"vemurafenib","Targeted therapies","","Other specified melanoma of skin","","Removed","nan","who.int"
"verapamil","Antiarrhythmic medicines","Parenteral > General injections > IV: 2.5 mg per  mL in 2 mL ampoule (hydrochloride)
Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)","Supraventricular tachyarrhythmia","","Added","C08DA01","who.int"
"verapamil","Antianginal medicines","Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)","Angina pectoris","","Added","C08DA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Other specified gliomas of brain","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Kaposi sarcoma of unspecified primary site","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Hodgkin lymphoma","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Other specified malignant neoplasms of the ovary","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Germ cell tumour of testis","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Anaplastic large cell lymphoma, ALK-negative","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Anaplastic large cell lymphoma, ALK-positive","","Added","L01CA01","who.int"
"vinblastine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)","Langerhans cell histiocytosis","","Added","L01CA01","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Unspecified malignant neoplasms of ill-defined or unspecified sites","","Removed","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Other specified gliomas of brain","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Malignant trophoblastic neoplasms of placenta","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Follicular lymphoma","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Kaposi sarcoma of unspecified primary site","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Rhabdomyosarcoma primary site","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Hodgkin lymphoma","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Diffuse large B-cell lymphomas","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Retinoblastoma","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Burkitt lymphoma including Burkitt leukaemia","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Malignant neoplasms of kidney, except renal pelvis","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Ewing sarcoma of bone and articular cartilage of unspecified sites","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Lymphoid leukaemia, not elsewhere classified","","Added","L01CA02","who.int"
"vincristine","Cytotoxic medicines","Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)","Langerhans cell histiocytosis","","Added","L01CA02","who.int"
"vinorelbine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial
Oral > Solid: 20 mg; 30 mg; 80 mg","Other specified malignant neoplasms of bronchus or lung","","Added","L01CA04","who.int"
"vinorelbine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial
Oral > Solid: 20 mg; 30 mg; 80 mg","Other specified malignant neoplasms of breast","","Added","L01CA04","who.int"
"vinorelbine","Cytotoxic medicines","Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial
Oral > Solid: 20 mg; 30 mg; 80 mg","Rhabdomyosarcoma primary site","","Added","L01CA04","who.int"
"voriconazole","Antifungal medicines","Parenteral > General injections > IV: 200 mg in vial powder for injection
Oral > Liquid: 40 mg per  mL powder for oral liquid
Oral > Solid: 50 mg tablet; 200 mg tablet","Chronic pulmonary aspergillosis","","Added","J02AC03","who.int"
"voriconazole","Antifungal medicines","Parenteral > General injections > IV: 200 mg in vial powder for injection
Oral > Liquid: 40 mg per  mL powder for oral liquid
Oral > Solid: 50 mg tablet; 200 mg tablet","Invasive aspergillosis","","Added","J02AC03","who.int"
"warfarin","Medicines affecting coagulation","Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","Other specified diseases of arteries or arterioles","","Added","B01AA03","who.int"
"warfarin","Medicines affecting coagulation","Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","Cerebral ischaemic stroke due to embolic occlusion","","Added","B01AA03","who.int"
"warfarin","Medicines affecting coagulation","Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","Venous thromboembolism","","Added","B01AA03","who.int"
"warfarin","Medicines affecting coagulation","Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)","Atrial fibrillation","","Added","B01AA03","who.int"
"water for injection","Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous","Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule","Unspecified appropriateness of dosing or administration without injury or harm","","Added","nan","who.int"
"whole blood","Blood and blood components","Parenteral > General injections > IV: ","Blood transfusion without reported diagnosis","","Added","nan","who.int"
"xylometazoline","Ear, nose and throat medicines [c]","Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL","Nasal congestion","","Added","R01AA07","who.int"
"yellow fever vaccine","Recommendations for certain regions","All vaccines should comply with the WHO requirements for biological substances.","Need for immunization against certain single viral diseases","","Added","J07BL01","who.int"
"zanubrutinib","Targeted therapies","Oral > Solid: 80 mg","Mantle cell lymphoma","","Removed","L01EL03","who.int"
"zidovudine","Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors","Parenteral > General injections > IV: 10 mg per  mL in 20 mL vial solution for IV infusion injection
Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 250 mg capsule; 300 mg tablet","Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified","","Added","J05AF01","who.int"
"zinc sulfate","Medicines for diarrhoea","Oral > Solid: 20 mg","Diarrhoea","","Added","A12CB01","who.int"
"zoledronic acid","Supportive medicines","Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle","Malignant neoplasm metastasis in bone or bone marrow","","Added","M05BA08","who.int"
